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Amphetamines (AMPH) are among the most widely misused drugs in the United States 
and worldwide. Currently, there are no pharmacological interventions for amphetamine-use 
disorder. A close examination of mechanism of action of AMPH identified protein kinase C 
(PKCβ) as a potential target for a new therapeutic intervention. The reinforcing effects of AMPH 
are elicited through an increase in extracellular dopamine levels in the brain. PKCβ inhibition 
attenuates AMPH-stimulated increases in dopamine levels in vivo and ex vivo, leading to the 
possibility that PKCβ inhibition decreases the reinforcing effects of AMPH. These findings 
highlight the potential for developing PKCβ inhibitors as a pharmacological intervention for 
AMPH-use disorder.  
 To assess the feasibility of utilizing PKCβ inhibitors as a treatment for AMPH-use 
disorders, I examined whether pharmacological inhibition of PKCβ attenuated AMPH-stimulated 
behaviors. I used the PKCβ inhibitors in proof-of-concept studies demonstrating that PKCβ 
inhibitors decrease AMPH-stimulated locomotor activity and AMPH self-administration. Using a 
self-administration model to investigate the reinforcing properties of AMPH, I showed that an 
intracerebroventricular injection of a PKCβ inhibitor 18 hr prior to a self-administration session 
decreased responding for AMPH under a fixed-ratio 5 schedule of reinforcement and shifted the 




PKCβ inhibitors decreased responding for AMPH under a progressive-ratio schedule of 
reinforcement, demonstrating that PKCβ inhibition decreased the reinforcing strength of AMPH 
and the motivation to work for AMPH. PKCβ inhibitors did not decrease responding for sucrose 
under a fixed-ratio or progressive ratio schedule, indicating that the doses tested did not inhibit 
general behavior. These properties are desirable for a pharmacological intervention for 
substance-use disorders and support the development of PKCβ inhibitors as new therapeutics for 
the treatment of AMPH-use disorder.  
Interestingly, my findings suggested that PKCβ inhibitors acted acutely to decrease 
AMPH-stimulated behaviors but also decreased AMPH-stimulated behaviors through a 
secondary mechanism. To probe these mechanisms, I compared locomotor activity and protein 
expression at different time points following administration of a PKCβ inhibitor into the nucleus 
accumbens (NAc) or ventral tegmental area (VTA). I found that PKCβ inhibition in the NAc 
acutely decreased AMPH-stimulated locomotor activity whereas PKCβ administration into the 
VTA required an extended period of time before attenuating locomotor activity. Furthermore, 
PKCβ levels were decreased in the VTA 18 hr following administration of a PKCβ inhibitor. 
These findings support the hypothesis that PKCβ inhibitors act through a secondary mechanism, 
possibly the downregulation of PKCβ, to decrease AMPH-mediated behaviors. Altogether, these 
findings support the use of PKCβ inhibitors as a new therapeutic for AMPH-use disorder and 
further our understanding of the mechanism by which the inhibitors act to decrease AMPH-







Chapter 1 Introduction 
Substance-use disorders 
Substance-use disorders are a serious public health concern worldwide. The Diagnostic 
and Statistical Manual of Mental Disorders (DSM-5) characterizes the criteria  for substance-use 
disorder as a pattern of use of drugs (including stimulants, sedatives, inhalants, and 
hallucinogens) that leads to physical or psychological dependence, as well as recurrent and 
increased use despite consequences, tolerance and withdrawal, and cravings (American 
Psychiatric Association 2013).  Many factors including genetics, mental health, the environment, 
and exposure to drugs are implicated in the development of substance-use disorders (NIDA 
2018a). A 2016 study estimated that nearly 300 million people worldwide used controlled 
substances during the previous year and 11% of people who use drugs can be diagnosed with a 
substance-use disorder (UNODC 2018). Within the United States of America, more than 63,000 
people died of drug misuse-related causes in 2015, with opioids, cocaine, and amphetamine-type 
stimulants representing the top drugs related to the deaths (UNODC 2016a). Substance-use 
disorders have cost the United States an estimated $700 billion in costs for criminal justice, 
health care, and loss of productivity (McCollister et al. 2017; NIDA 2017). With the substantial 
costs of substance-use disorders on individuals and communities, there is a strong need for more 




Currently, the most common treatments for substance-use disorders are behavioral 
therapies and community interventions (Carroll and Onken 2005; NIDA 2018b) . Behavioral 
therapies may be implemented in different forms, such as providing incentives for a decrease in 
drug use or training patients to recognize risks and situations associated with drug use (Carroll 
and Onken 2005). One of the limitations to the effectiveness of these treatments are the vast 
array of factors that play into the maintenance of substance-use disorders, often making it 
necessary to combine different types of interventions (UNODC 2016b). Pharmacological 
interventions can be effective for certain classes of drugs such as opioids and nicotine; however, 
there are no accepted medications to treat addiction to other classes of drugs, leaving behavioral 
therapy as the primary source for treatments (UNODC 2016b). Thus, research developing novel 
pharmacological interventions to supplement behavioral therapies is necessary to expand the 
effectiveness of substance-use therapeutic strategies.  
Investigating novel treatments for drug abuse 
 Behavioral pharmacology has long been a field vital to the understanding of drugs of 
abuse and the development of pharmacological therapeutics. In humans and animals, drugs of 
abuse can produce physiological effects and changes in observable behaviors such as 
hyperactivity or dependence. However, it is often called into question whether these measures 
contribute to or influence the abuse liability of psychoactive drugs. Abuse liability can be better 
assessed by exploring behaviors controlled by reinforcement, motivation, and learning.  Some of 
the early studies within the field of behavioral pharmacology relied on techniques developed by 
prominent psychologists B.F. Skinner and Ivan Pavlov to show that psychoactive drugs can 
selectively alter or control different behaviors (Dews 1955; Pickens 1977). These studies began 




Animal behavior can be used to study the mechanisms of drug action, to evaluate abuse 
liability of drugs, and to assess therapeutics for the treatment of substance-use disorders 
(Griffiths et al. 1979; Henningfield et al. 2016). Methods such as conditioned-place preference, 
intracranial self-stimulation, drug discrimination, and drug self-administration are some of the 
most commonly used techniques to address these types of studies. These techniques rely on the 
concepts of reward and reinforcement; reward is an event with a positive value (i.e. food or drug) 
and positive reinforcement is an increase in the behavior paired with a reward. Well-designed 
animal studies can model different aspects of substance-use disorders such as reward and 
reinforcement, drug-taking and drug-seeking, environmental variables, and relapse.  
Conditioned-place preference (CPP) is a technique that examines the rewarding 
properties of drugs of abuse. In this assay, rodents are exposed to different environments 
(different floor patterns or coloring) and are conditioned to associate one environment with an 
injection of drug and the other environment with an injection of vehicle. Following a 
conditioning period, the animals are placed in the chambers and allowed to roam freely. The time 
spent in the drug-paired side of the box as opposed to the vehicle-paired side is recorded. An 
increase in time spent on the drug-paired side indicates a preference for the drug, whereas a 
decrease indicates if the drug is aversive (Prus et al. 2009). Psychostimulants have been well 
characterized in place-preference assays and are known to produce CPP (Itzhak and Martin 
2002; Spyraki et al. 1982). Pharmacological and genetic studies with CPP are used to study 
mechanisms behind drug reward, to model relapse, and to screen therapeutics for the treatment of 
substance-use disorders (Bardo and Bevins 2000; Napier et al. 2013). This technique can 
additionally be used to probe questions on cue-related memory and learning (McIntyre et al. 




not address other behaviors associated with drugs of abuse, such as drug-taking behaviors, 
making it necessary to include additional techniques in the studies of drugs of abuse (Nader 
2016).  
Intracranial self-stimulation (ICSS) is another method used to model the effects of drugs 
of abuse. In these studies, animals are implanted with intracranial electrodes that deliver 
electrical stimulation to the regions of the brain associated with motivation and reward such as 
the ventral tegmental area (VTA)  (Wise 1996). Animals make responses on a manipulandum in 
order to receive electrical stimulation. Early studies with this technique demonstrated that 
stimulation in the VTA or hypothalamus are reinforcing; an animal will increase responding that 
has been paired with the electrical stimulation, or the reward (Olds and Milner 1954).  By 
varying the frequency of the stimulations, it is possible to generate rate-frequency curves 
comparing the frequency of the stimulation to the number or rate of responses. Animals display 
increased levels of responding for higher frequencies, which are more rewarding (Wise 1996).  
Drugs of abuse generally shift the rate-frequency curves to the left; the stimulation threshold is 
lower, and animals respond more for lower frequencies in the presence of certain drugs. The 
results from ICSS studies are used as an indicator of a drug’s abuse liability (Negus and Miller 
2014). ICSS is also used to identify regions in the brain important for reward circuitry (Koob 
2009). ICSS is an indirect method to study drugs of abuse because it does not measure drug-
taking or drug-seeking behaviors, so it is often used in conjunction with other behavioral assays.  
Drug discrimination is a technique that is used to measure the subjective effects of a 
drugs of abuse and provide insight into abuse liability of the drugs tested, their underlying 
mechanisms, and potential therapeutics (Holtzman 1990; Porter et al. 2018; Rocha et al. 2008). 




often a food pellet. The animals are trained to make one response if they have been treated with a 
CNS active drug and another response if they receive an injection of saline. During training, 
animal only earn a food reward by making the injection-appropriate response. Once a drug has 
been established as a discriminative stimulus, the interoceptive (or subjective) properties of a 
novel drugs can be evaluated. Drug discrimination studies are used by government agencies in 
order to determine if a novel drug should be regulated or controlled; if a new compound 
generalizes to a controlled substance, such as morphine or amphetamine, then the new compound 
likely has the potential to be abused (Nader 2016; Rocha et al. 2008). Some limitations to the use 
of drug discrimination assays are that there are many variables that can affect the results of the 
studies, such as the training drug used and dose (Grant et al. 2000; Nader 2016). As with ICSS 
and CPP, this technique is a useful, but indirect, tool for studying drugs of abuse since it doesn’t 
directly model behaviors associated with substance use disorders such as drug-taking or drug-
seeking behaviors. Therefore, drug discrimination studies are often combined with more direct 






Figure 1.1 Operant boxes for rodent self-administration 
Image displays a rat in an operant chamber with two nose pokes and a pellet dispenser. 
The “active” nose poke is highlighted in yellow and indicates the active nose poke in which a 
response results in drug delivery (also known as the discriminative stimulus). Artwork by 
Michael Ferguson, University of Michigan, 2017. 
 
The gold standard technique used to study drugs of abuse and abuse liability is drug self-
administration. Animals readily self-administer certain drugs commonly abused by humans such 
as cocaine, amphetamine, and opioids (Griffiths et al. 1979; O'Connor et al. 2011), thus this 
technique is often used to examine the reinforcing properties of drugs of abuse and determine the 
abuse liability of novel drugs. Self-administration procedures also model different aspects of 
substance-use disorders such as drug-taking behaviors, drug-seeking behaviors, and relapse, 
making them a useful, direct tool for studying drugs of abuse. Governmental regulatory agencies 




(O’Connor et al. 2011). These studies allow animals to self-administer drugs of abuse orally, 
intravenously, or through inhalation. In standard self-administration studies, animals are placed 
in an operant box (Figure 1.1) where they can respond on levers or other manipulanda for a 
reward. When the animal responds under a specific schedule, it receives a reward such as food or 
drug. A reward is considered a reinforcer if it increases the likelihood of a behavior (i.e. level 
pressing) occurring. A discriminative stimulus (such as a light in the nose poke) may signal to 
the animal the availability of a reinforcer. A conditioned stimulus is often paired with delivery of 
the reinforcer; for example, a tone or light occurring every time the animal receives a reinforcer. 
Conditioned stimuli often carry their own salience, likely due to their association with a reward 
(Flagel et al. 2011). One of the most common schedules used is the fixed-ratio (FR) schedule of 
reinforcement, where a set number of responses always results in the delivery of a reinforcer. FR 
schedules are among the simplest and most common procedures to use when studying drug-
taking behavior (Panlilio and Goldberg 2007; Spealman and Goldberg 1978). Utilizing self-
administration as a model for substance-use disorders is a highly useful tool but inevitably 
contains some limitations, mainly that self-administration models do not accurately model all the 
social and environmental factors associated with drug use. Despite these limitations, self-
administration techniques remain one of the best tools to study drugs of abuse.  
More intricate schedules of reinforcement can model drug-seeking behavior and examine 
the reinforcing efficacy of different drugs. One example of these more complex schedules is the 
progressive-ratio (PR) schedule of reinforcement. Under PR schedules of reinforcement, the 
work requirement (number of responses) for the delivery of a reward increases within or between 
sessions, until the animal no longer completes the necessary work requirement. The final ratio 




motivation (Hodos and Kalman 1963; Markou et al. 1993). Furthermore, comparing the 
breakpoint across different drug reinforcers allows experimenters to draw conclusions about the 
reinforcing efficacy of the drugs (Brady 1991; Hodos 1961; Richardson and Roberts 1996). 
Richardson and Roberts have argued that while responding under an FR schedule of 
reinforcement provides data on whether or not a drug can act as a reinforcing stimulus, a benefit 
of a PR schedule is that it provides quantitative data on the reinforcing or motivational strength 
of drugs (Richardson and Roberts 1996; Roberts and Richardson 1992).  
All of the assays above can be used to identify and assess novel therapeutics for the 
treatment of substance-use disorders (Haney and Spealman 2008; Mello and Negus 1996; Nader 
2016).  An ideal therapeutic would decrease responding for the drug or alter its reinforcing 
efficacy in self-administration models without altering all operant responding. This can be 
assessed by examining if the drug in question alters responding for a natural reinforcer such as 
food. Multiple doses of drugs need to be studied to determine the extent of the drugs’ actions; an 
ideal treatment for drug abuse would not simply shift the dose-effect curve for drug self-
administration to the right but dampen responding for a drug (Mello and Negus 1996). Strategies 
such as CPP, ICSS, drug discrimination, and self-administration require considerable time and 
training in order to collect data, therefore behaviors that do not require training, such as 
locomotor activity, are used as a quick and early screening process when identifying new 
medications (Nader 2016). Altogether, these techniques have been used during the development 
of medications (i.e. buprenorphine, varenicline) that successfully treat substance-use disorders 
(Biala et al. 2010; Wiebelhaus et al. 2016; Winger et al. 1992) 




Drugs that are commonly abused are divided into many different categories. One of the 
categories of drugs most commonly abused are psychostimulants. Psychostimulants, including 
caffeine, nicotine, cocaine, and amphetamine, are named due to their ability to stimulate the 
central nervous system (Favrod-Coune and Broers 2010) and can result in arousal and alertness. 
Within the larger class of psychostimulants are indirect sympathomimetics, which increase 
norepinephrine (Burn and Rand 1958; Koob et al. 2014) and dopamine levels in the brain;  
(McCreary et al. 2015; Sulzer 2011); this class includes amphetamine and cocaine. Additional 
classes of abused drugs include depressants such as alcohol, opioids (e.g. heroin), and cannabis. 
One thing these drugs all have in common is that they increase dopamine levels in the brain 
(Sulzer 2011).  
 
 
Figure 1.2 Main dopaminergic pathways in the brain 
Adapted from Goodman and Gilman’s: The Pharmacological Basis of Therapeutics, 13 




the tuberoinfundibular pathway in red. The mesolimbic pathway is highlighted in yellow (Sibley 
et al. 2017). 
 
Dopamine is a catecholamine that is important for the body and brain. Dopamine within 
the body plays a role in cardiovascular and renal functions (Missale et al. 1998). Within the 
brain, dopamine is important for functions including learning, movement, attention, and memory 
(Sibley 1999). Dysregulation of dopamine has been implicated in diseases such as Parkinson’s 
disease, schizophrenia, and substance-use disorders (Abi-Dargham 2014; Ehringer and 
Hornykiewicz 1960; Volkow et al. 2004). The main dopaminergic pathways in the brain are the 
mesolimbic pathway, the mesocortical pathway, the nigrostriatal pathway, and the 
tuberoinfundibular pathway (Figure 1.2). The mesolimbic pathway has been identified as an 
important pathway that regulates reward, including natural rewards such as food and sex as well 
as drugs of abuse. This pathway begins with dopaminergic cell bodies in the ventral tegmental 
area (VTA) that extend to the nucleus accumbens (NAc). Drugs of abuse increase activity of 
dopaminergic neurons along this pathway, and dopamine increase in the NAc is important for the 
salience of rewards (Di Chiara and Imperato 1988; Volkow et al. 2004). 
Dopamine is synthesized when tyrosine is converted to L-3,4-dihydroxlphenylalanine (L-
DOPA) through the addition of a hydroxyl group to tyrosine by tyrosine hydroxylase. L-DOPA 
is then converted to dopamine through the removal of a carboxyl group by aromatic amino acid 
decarboxylase. The tyrosine hydroxylase conversion of tyrosine to L-DOPA is considered the 
rate-limiting step in dopamine synthesis and is important for negative feedback to regulate 
dopamine levels (Meyer and Quenzer 2005). Dopamine can be further metabolized to 
norepinephrine by dopamine β-hydroxylase and degraded by monoamine oxidase (MAO), 




active within the presynaptic neuron, storage in synaptic vesicles prevents MAO from degrading 
dopamine. Dopamine is transported into vesicles through the vesicular monoamine transporter 
(VMAT). When an action potential depolarizes the neuron, dopamine is released into the 
extracellular space via exocytosis. Once released, dopamine can bind to presynaptic and 
postsynaptic dopamine receptors. Postsynaptic dopamine receptors are G-protein coupled 
receptors (GPCR) that are classified as D1-like receptors (coupled to stimulatory Gs proteins) and 
D2-like receptors (coupled to the inhibitory Gi/o proteins). Activation of these receptors modulate 
functions such as motor activity, attention, and sleep (Beaulieu and Gainetdinov 2011). D2-like 
receptors are also found on postsynaptic neurons as well as presynaptic neurons and are involved 
in dopamine regulation (further discussed in the next session). 
Dopamine regulation 
Fine-tuning dopaminergic signaling is important for proper physical and mental health. In 
order to terminate dopaminergic signaling, dopamine is cleared from the extracellular space by 
degradation, diffusion or reuptake into neurons. The machinery necessary for reuptake is the 
dopamine transporter (DAT). DAT is a transmembrane protein in the presynaptic neuron that 
removes dopamine from the extracellular space into the neuronal terminal where it is repackaged 
into vesicles or recycled. DAT has 12 transmembrane domains and intracellular-facing N-
terminal and C-terminal domains. These domains contain multiple sites for posttranslational 
modifications such as phosphorylation, palmitoylation, and ubiquitination that help modulate 
DAT function, degradation, and/or trafficking (Vaughan and Foster 2013). A crystal structure 
from a homologous Na+, Cl- dependent transporter, LeuT, suggests that DAT exists in both 
inward (intracellular)-facing and outward (extracellular)-facing conformations; movement 




neuron. Along with two Na+ and one Cl-, dopamine binds to DAT when it is in its outward-
facing conformation. When DAT shifts to its inward-facing conformation, dopamine and the ions 
dissociate from DAT and are released into the cytoplasm. The Na+ and Cl- gradients drive the 
transport (Pramod et al. 2013; Shan et al. 2011; Yamashita et al. 2005).  
An additional mechanism of dopamine regulation is through the dopamine receptors. 
Several GCPRs in the D2-like family, D2, D3, and D4 receptors, are found presynaptically and are 
referred to as autoreceptors. Activation of these receptors can regulate dopamine through 
multiple mechanisms: by decreasing exocytotic release of dopamine, increasing dopamine 
uptake and altering rates of dopamine synthesis (Beaulieu and Gainetdinov 2011; Joseph et al. 
2002). Multiple studies have suggested that D2 or D3 activation can decrease the rate of firing in 
dopaminergic neurons, likely through activation of potassium channels or inactivation of calcium 
channels, which ultimately decreases extracellular dopamine release (Kuzhikandathil et al. 1998; 
Neve et al. 2004). Studies have also indicated that autoreceptor activation increases DAT 
activity, resulting in an increase in dopamine clearance from the synapse (Wu et al. 2002). 
Further studies have suggested that D2 and D3 receptor activation affects DAT trafficking, with 
short exposures to D3 agonists increasing surface DAT and long exposures increasing DAT 
internalization (Bolan et al. 2007; Zapata et al. 2007). Additionally, autoreceptor activation 
inhibits tyrosine hydroxylase, thus decreasing dopamine levels within the neuron (O'Hara et al. 
1996). 
Amphetamines 
History of amphetamine  
One of the most commonly misused class of drugs worldwide is amphetamines, a class of 




methamphetamine (Ecstasy). Natural amphetamines, such as components of the ephedra plant, 
have been used for thousands of years worldwide and are known for their stimulating properties. 
Japanese chemists studying ephedra first extracted l-ephedrine and r-pseudoephedrine from 
ephedra in 1885 and proposed its use for pupil dilation. Later studies revealed that ephedrine was 
a sympathomimetic and scientists sought to use ephedrine as a treatment for asthma (Lee 2011). 
Dr. Gordon Alles began focusing on amphetamine during the search for a better and cheaper 
drug with ephedrine-like actions (Rasmussen 2015). Smith, Kline, and French (currently 
GlaxoSmithKline) began marketing Benzedrine, a racemic mixture of d- and l-amphetamine, as a 
decongestant. Despite the failure with original intended use of amphetamine, asthma, researchers 
began looking at amphetamine to treat a variety of conditions such as narcolepsy, dysmenorrhea, 
and depression (Rasmussen 2006). Amphetamine gained popularity when it was discovered that 
it increased alertness and performance on intelligence tests (Davidoff et al. 1937; Nathanson 
1937). Charles Bradley (M.D.) gave Benzedrine to children with behavioral disorders and found 
that Benzedrine subdued behaviors in some children and stimulated behavior others, findings 
that were important in the classification and treatment of attention deficit hyperactivity disorder 
(ADHD) (Strohl 2011). Amphetamines are used to this day in the treatment of ADHD, 
commonly in the form of Adderall (3:1 d-amphetamine to l-amphetamine).  
 Despite their medical importance, amphetamines have been historically misused 
worldwide. Misuse of Benzedrine was identified early among university students and misuse of 
Benzedrine inhalers were particularly an issue in the military during World War II (Davies 1939; 
Jackson 1971). During the 1960s, there were many reports on the increased use of amphetamines 
beyond therapeutic doses and for non-prescribed purposes (Kiloh and Brandon 1962; Rasmussen 




psychiatric disorders such as psychosis (Connell 1966). Currently, amphetamine misuse is still 
prevalent worldwide. The Monitoring the Future study, which evaluates drug use in high school 
students, found non-medical usage of amphetamines to be the highest reported drug used among 
high school students after alcohol and marijuana (Miech et al. 2018). Furthermore, a survey from 
2017 estimated over 570,000 people in the United States with a stimulant-use disorder and over 
960,000 people with a methamphetamine-use disorder (SAMHSA 2018). From the 2016 
National Surveys on Drug Use and Health, Compton et al. (2018) showed that over 8% of adults 
who used prescription stimulants in the previous year had a substance-use disorder. From 2005 
to 2016, there was a 35% increase in amphetamine confiscations globally along with a large 
increase in prescription stimulant consumption (Rasmussen 2006; UNODC 2018). Furthermore, 
diagnoses of ADHD are becoming more common (Xu et al. 2018), leading to more prescriptions 
of amphetamines. As extensive misuse of amphetamines has serious consequences on physical 
and mental health, efforts to decrease amphetamine use are important and necessary. 
Mechanism of action 
Amphetamines are considered indirect sympathomimetics and are structurally similar to 
dopamine and norepinephrine (Figure 1.3). They increase dopamine, norepinephrine, and to a 
lesser extent serotonin levels in the brain (Fleckenstein et al. 2007). Amphetamines are thought 
to act at monoamine transporters to increase extracellular dopamine (through DAT), 
norepinephrine, and serotonin levels. Due to their similar structure, amphetamines can act as 
substrates at DAT to enter the neurons along with sodium, competing with dopamine for uptake 
(Azzaro et al. 1974; Zaczek et al. 1991). Once in the neuron they cause changes that ultimately 
result in increased levels of extracellular dopamine, which are associated with the reinforcing 






Figure 1.3 Structure of norepinephrine, dopamine, amphetamine 
 
Amphetamine also alters extracellular dopamine levels by affecting machinery necessary 
for negative feedback. Studies have demonstrated that long exposures to amphetamine can 
decrease D2/D3 autoreceptor function, potentially through increased internalization of 
autoreceptors (Calipari et al. 2014; Luessen et al. 2016). This would lead to a decrease in the 
ability to regulate dopamine release. The findings on how amphetamine affects tyrosine 
hydroxylase activity have been mixed. Early studies showed that amphetamine exposure can lead 
to an increase in tyrosine hydroxylase  activity, causing an increase in dopamine synthesis 
(Larsen et al. 2002; Mandell and Morgan 1970). Other studies found a decrease in tyrosine 
hydroxylase activity and suggested the differing results may be specific to tissue type or dose of 
amphetamine (Besson et al. 1973; Harris et al. 1975; Sulzer et al. 2005). Additional mechanisms 
may include activity at or regulation of trace amine-associated receptor-1 (TAAR1). TAAR1 is a 
GPCR coupled to Gs stimulatory proteins that can be activated by amphetamine. Amphetamine 
has a higher affinity for TAAR1 than DAT (Ki = 0.23 µM for rat TAAR1, 3.6 µM for rat DAT) 
(Ritz and Kuhar 1989; Simmler et al. 2016). Activation of TAAR1 decreases dopamine uptake 




dopamine levels, the canonical mechanism by which amphetamine increases extracellular 
dopamine levels is through its actions at the vesicular monoamine transporters (VMAT) and 
DAT.  
 
Figure 1.4 Mechanism of action of amphetamine 
Adapted from “Drugs of Abuse”, Katzung BG, Basic and Clinical Pharmacology 2017. This 
image shows a dopaminergic neuron in the presence of amphetamine. Amphetamine (red circles) 
enters through DAT and causes the displacement of dopamine (white circles) from the vesicles 
and dopamine release through DAT (Lüscher 2017).  
 
 
Years of research have suggested that amphetamine can enter a neuron via DAT, increase 
cytoplasmic dopamine, and ultimately reverse the direction of dopamine transport through DAT 
(Figure 1.4). The role of DAT in the action of amphetamine was determined in studies showing 
that DAT uptake blockers decrease the ability of amphetamine to increase extracellular 
dopamine (Raiteri et al. 1979; Sulzer et al. 1995). While amphetamine can elicit an increase in 
dopamine levels with DAT alone, the presence of VMAT enhances the effects of amphetamine 




Giros et al. (1996) who showed that amphetamine did not elicit an increase in locomotor activity 
in DAT knockout mice.  The mechanisms by which amphetamine affects vesicular and cytosolic 
dopamine are regulated by factors such as dose of amphetamine. Butcher et al. (1988) utilized 
microdialysis to demonstrate that amphetamine preferentially releases newly synthesized 
dopamine found in the cytosol, however studies with reserpine also demonstrated the importance 
of VMAT in the mechanism of large doses of amphetamine. Cadoni et al. (1995) showed that 
reserpine, which decreases stores of dopamine in vesicles, blocked amphetamine-stimulated 
dopamine release with large doses of amphetamine (2 mg/kg) but not low doses of amphetamine 
(0.5 mg/kg).  The “weak base” hypothesis is a widely accepted explanation for amphetamine-
stimulated increases in cytosolic dopamine. As amphetamine is weak base, it is protonated and 
accumulates in vesicles. This leads to the alkalization of vesicles, which disrupts the proton 
gradient necessary for transport of dopamine into the neuron (Sulzer and Rayport 1990). Another 
theory suggests that the alkalization of the vesicles occurs when amphetamine is transported into 
the vesicles via VMAT and is exchanged for protons (Freyberg et al. 2016). Once in the 
cytoplasm, dopamine is released into the synapse through DAT. Multiple mechanisms have been 
proposed for the reversal of DAT function. One theory for efflux through DAT is called the 
“facilitated exchange model”. DAT has an outward- and inward-facing conformation that directs 
the direction of substrate movement. In the facilitated exchange model, transport of amphetamine 
into the neuron moves DAT from the outward-facing conformation to the inward-facing 
information and allowing for dopamine efflux (Sulzer et al. 2005). Harald Sitte and the Pifl 
group found efflux through DAT had a stronger correlation to currents induced by DAT 
substrates than substrate uptake, calling into question the facilitated exchange model (Sitte et al. 




efflux (Khoshbouei et al. 2003). Post translational modifications such as phosphorylation have 
also been implicated in the reversal of DAT function (Vaughan and Foster 2013).  
Protein kinase C 
One of the most studied enzymes in relation to DAT phosphorylation is protein kinase C 
(PKC). PKC is a protein in the serine-threonine kinase family and is common in many signal 
transduction pathways. PKC is important for many different physiological processes such as 
regulation of angiogenesis and the immune response and can lead to the development of diseases 
such as diabetes and cancer (Mochly-Rosen et al. 2012). There are many different isoforms of 
PKC and they are divided into three different classes based on their structure: classical or 
conventional PKC (α, βI, βII, γ), atypical PKC (δ, θ, η, ε), and novel PKC (ζ, λ, ι) isoforms. All 
PKC isoforms contain a regulatory domain and a catalytic domain, but they differ primarily in 
their regulatory domain. The regulatory domain of classical PKCs contains a pseudo-substrate 
(important for keeping PKC inactive), two diacylglycerol binding domains, and a calcium 
binding domain (Figure 1.5). The catalytic domain is made up of an ATP-binding domain and a 
substrate binding domain. Novel PKCs do not contain a calcium-binding domain, and atypical 
PKCs contain neither a calcium-binding domain nor a diacylglycerol-binding domain. In their 
inactive conformation, the pseudo-substrate domain is bound to the substrate domain. Following 
binding of Ca2+, PKC translocates to the plasma membrane, binds to diacylglycerol, and 
undergoes a conformational change causing the dissociation of the pseudo-substrate domain 
from the substrate binding domain, allowing actual substrates to bind to PKC and be 




   
Figure 1.5 Protein kinase C activation 
The structure of the classical PKCs is shown above an image demonstrating PKC activation. 
PKC in its active form is bound Ca2+, diacylglycerol (DAG), and the plasma membrane (Spitaler 
and Cantrell 2004).  
 
Classical isoforms of PKC are highly expressed throughout the brain and important for 
different functions within the brain (Kikkawa et al. 1983). Some substrates of PKC include 
growth-associated protein 43 (GAP43), a protein important for long term potentiation and 
memory, NMDA and AMPA receptors, proteins important for neurotransmission, and DAT 
(Callender and Newton 2017; Oehrlein et al. 1996; Vaughan et al. 1997). Early studies 
demonstrated that PKC activation alters neurotransmitter release (Zurgil and Zisapel 1985), but 
Cecilia Giambalvo provided some of the first direct evidence for a relationship between PKC and 
dopamine release, showing drugs that increase extracellular dopamine levels also increase PKC 




She demonstrated that amphetamine (0.3-3.0 mg/kg) would increase PKC in membrane 
preparations and these effects were separate from autoreceptor activation, leading her to 
conclude that PKC modulates DAT (Giambalvo 1992a; b).  Cloning of DAT in the early 1990s 
led to the discovery of multiple intracellular consensus sequences for PKC phosphorylation in 
the N-terminal region (Shimada et al. 1991). Activation of PKC with phorbol 12-myristate 13-
acetate (PMA) increased phosphorylation of DAT and decreased dopamine uptake (Copeland et 
al. 1996; Huff et al. 1997; Kitayama et al. 1994), likely due to increased DAT internalization 
(Melikian and Buckley 1999).  
In addition to showing PKC played a role in dopamine inward transport, many studies 
also elucidated its role in reverse-transport, particularly in relation to amphetamine. Iwata et al. 
(1997) demonstrated that amphetamine increased PKC activity in vivo. Increased Ca2+ levels in 
the cytosol in response to amphetamine is most likely responsible for an increase in PKC 
activation (Giambalvo 2004). PKC activation increased dopamine efflux through DAT, 
mimicking the effects of amphetamine (Cowell et al. 2000). Conversely, PKC inhibition 
decreased the effects of amphetamine in vitro (Giambalvo 1992b; Kantor and Gnegy 1998). 
Removal of the first 22 amino acids from the N-terminal region of DAT (containing the PKC 
phosphorylation sites) inhibited amphetamine-stimulated dopamine release (Khoshbouei et al. 
2004), demonstrating that phosphorylation of DAT was likely important for the mechanism of 
action of amphetamine. Of all the PKC isoforms, PKCβII is the most important for amphetamine 
action. PKCβI and II are splice variants of the same protein differing in the C-terminal domain 
(Ono et al. 1986). Overexpression of PKCβII in cell models results in increased amphetamine-
stimulated dopamine release, as compared with overexpression of PKCβI and PKCα (Johnson et 




amphetamine-stimulated dopamine release in their striatal tissue and a decrease in amphetamine-
stimulated locomotor activity (Chen et al. 2009). Based on this mechanism, PKCβ has been 
proposed as a potential therapeutic target for treating amphetamine use disorder. 
Therapeutics for amphetamine-use disorder 
There is currently no known pharmacological therapeutic for the treatment of 
amphetamine-use disorder and the standard therapy currently only involves behavioral therapies. 
Thus, the development of new therapeutic options is a necessity. With the current knowledge 
about the mechanism of action of amphetamine, multiple targets have been proposed as potential 
therapeutics for amphetamine-use disorders. These targets include dopamine antagonists, VMAT 
inhibitors, DAT inhibitors and PKC inhibitors.  The targets discussed in the following 
paragraphs are all in various stages of development.  
One target for amphetamine-use disorder is to block signaling downstream induced by 
amphetamine. This has led to the testing of drugs targeting dopamine receptors as potential 
therapeutics. D2 partial agonists act as an agonist in the presence of low dopamine levels and an 
antagonist in the presence of high dopamine levels and decrease amphetamine-stimulated 
locomotor activity (Clark et al. 1991). Aripiprazole deceased methamphetamine self-
administration under an FR and PR schedule of reinforcement and attenuated subjective effects 
in human subjects (Stoops et al. 2006; Wee et al. 2007). Despite these promising results, 
aripiprazole was not significantly different from a placebo treatment in larger scale trials (Coffin 
et al. 2013). Another area that is currently being explored is the development of D3 receptor 
antagonists. Amy Newman’s group has done extensive work developing D3-selective antagonists 
in rodent models. They have demonstrated that D3 receptor antagonists decrease 




cue-induced reinstatement (Higley et al. 2011a; Higley et al. 2011b). Despite the promising 
preclinical results, clinical studies investigating the role of D3-selective antagonists for 
substance-use disorders have not shown any promise, though buspirone, a non-selective D3 
antagonist, may help patients undergoing withdrawal from different drugs of abuse. (Le Foll et 
al. 2014) 
Another target for treating amphetamine use disorders is the monoamine transporters. 
Studies with VMAT2 inhibitors, such as lobeline, have shown that VMAT inhibitors can 
decrease amphetamine-stimulated locomotor activity. Lobeline decreases methamphetamine self-
administration under an FR5 schedule of reinforcement, but an acute pretreatment also decreased 
sucrose self-administration (Harrod et al. 2001; Miller et al. 2001). Human trials with VMAT2 
inhibitors are still in the early stages and have demonstrated lobeline is a safe drug with an 
aversive taste that could deter compliance (NIDA 2916). Other VMAT2 inhibitors for the 
treatment of substance-use disorders are still in the early stages of development (Nickell et al. 
2014).  
DAT inhibitors are another class of drugs that have been a focus of amphetamine-use 
disorder therapeutics. One DAT inhibitor that has been widely studied is modafinil, but it also 
has actions other than DAT inhibition. Modafinil decreases responding under an FR1 schedule of 
reinforcement for methamphetamine and also blocks cue- and drug-primed reinstatement 
(Reichel and See 2012). Small scale clinical trials showed some promise for the efficacy of 
modafinil to decrease methamphetamine use and craving (McElhiney et al. 2009) but larger trials 
showed only a modest decrease in methamphetamine use and no change in craving (Shearer et al. 
2009). A concern about DAT inhibition is that a drug increasing extracellular dopamine (as 




generalizes to cocaine in a discrimination assay and is self-administered by monkeys at high 
doses (Gold and Balster 1996). This has led to concerns that any therapeutic blocking DAT will 
contain its own abuse liability. 
Additional targets for amphetamine-use disorder therapeutics are TAAR1 agonists. 
TAAR1 agonists block the development of methamphetamine sensitization and decrease 
methamphetamine self-administration, shifting the dose effect curve downward, and block cue- 
and drug-induced reinstatement (Jing et al. 2014). Despite their promise, the exact mechanism of 
TAAR agonist action has not been characterized (Liu and Li 2018). Outside of the dopamine 
system, gamma-aminobutyric acid (GABA) agonists, antidepressants, opioid antagonists, and 
selective serotonin reuptake inhibitors have also been considered as potential therapeutics for 
different aspects of amphetamine-use disorders (Cao et al. 2016; Morley et al. 2017).  
A promising target for amphetamine-use disorder therapeutics is PKC inhibitors. As 
mentioned in the previous section, PKC plays an important role in the action of amphetamine, 
and multiple studies have demonstrated that inhibition of PKC blocks amphetamine-stimulated 
dopamine release (Johnson et al. 2005; Kantor and Gnegy 1998; Loweth et al. 2009). 
Additionally, direct injection of general PKC inhibitors into the NAc reduces amphetamine-
stimulated locomotor activity (Browman et al. 1998). The role of PKCβ specifically in 
amphetamine-stimulated dopamine release was further confirmed utilizing genetic models of 
PKCβ inhibition and in microdialysis studies with PKCβ-selective drugs, enzastaurin and 
ruboxistaurin (Chen et al. 2009; Zestos et al. 2016). The behavioral effects of PKC inhibition 
may be due to more than the ability of PKC to modulate DAT as PKC inhibition has also been 




There are very few known isoform-selective PKC inhibitors. Enzastaurin and 
ruboxistaurin are two PKCβ-selective inhibitors developed by Eli Lilly (Figure 1.6). These drugs 
inhibit PKCβ with a Ki of 5-6 nM by binding to the ATP-binding site of the catalytic domain of 
PKC, preventing activation (Faul et al. 2003). These compounds were developed for the 
treatment of glioblastomas and diabetic retinopathy. Both drugs made it up to Phase III clinical 
trials, where they failed due to an inability to meet clinical endpoints (Bourhill et al. 2017). One 
important finding that these drugs displayed a good safety profile with little to no serious adverse 
events (Carducci et al. 2006; Javey et al. 2010). They have a limited therapeutic potential due to 
their low bioavailablity; however, they make good tools to study PKCβ inhibition in animal 
models and cellular studies. Enzastaurin and ruboxistaurin have been used in proof of principle 
studies that show the promise of PKC inhibitors as viable therapeutics (Zestos et al. 2016).  
There is a dearth of bioavailable PKC inhibitors that can cross the blood-brain barrier 
(Chico et al. 2009). One brain-permeable PKC inhibitor that has been identified is tamoxifen. 
Tamoxifen is known for its effects as a selective estrogen receptor modulator and has many 
adverse effects that could limit compliance; however, it is also a non-selective PKC inhibitor. 
Repeated tamoxifen administration decreases amphetamine-stimulated locomotor activity (Einat 
et al. 2007) and has been investigated as a treatment for bipolar mania, which is commonly 
modeled by acute injections of amphetamine in rodents (Zarate et al. 2007).  Recently there has 
been an effort to identify new PKC inhibitors, utilizing tamoxifen as a scaffold (Carpenter et al. 
2016). The new PKC inhibitors have been designed to possess brain permeability and PKC 
inhibition with no affinity for estrogen receptors. The most promising of these drugs, 6c, can 




Further development of 6c and other compounds from the tamoxifen scaffold would pave the 
way for a new wave of potential therapeutics for amphetamine-use disorder. 
While strides have been made to examine the effects of PKC inhibitors on amphetamine, 
at this point little has been done to examine whether these drugs alter the reinforcing effects of 
amphetamine. Inhibition of PKC decreases quinpirole-induced reinstatement of responding for 
cocaine (Ortinski et al. 2015) and amphetamine CPP (Aujla and Beninger 2003), suggesting that 
PKC plays a role in the rewarding properties of these stimulants. However, very little work has 
been done to investigate whether these drugs alter drug-taking behaviors. We have shown that 
the non-selective PKC inhibitor 6c decreases amphetamine self-administration behavior under an 
FR5 schedule of reinforcement (Carpenter et al. 2017), but no work has been published with 
PKCβ-selective inhibitors. Showing that PKCβ-selective inhibitors decrease the reinforcing 
effects of amphetamine will go a long way towards demonstrating their usefulness as a 
therapeutic for substance-use disorders.    
 
Figure 1.6 Chemical structures of enzastaurin, ruboxistaurin, and 6c 
Summary and hypothesis 
 There are currently no good pharmacological interventions for the treatment of 




amphetamine have identified PKCβ as a potential target for novel substance-use disorder 
therapeutics. The goal of my thesis is to characterize the effects of PKCβ inhibitors on 
amphetamine-mediated behaviors, especially drug-taking behaviors, in order to determine their 
feasibility as therapeutic interventions. I will show that PKCβ inhibitors decrease amphetamine-
mediated behaviors and decrease the reinforcing effects of amphetamine. I will also propose a 
novel mechanism by which PKCβ inhibitors are acting to reduce amphetamine-mediated 
behaviors. These findings strongly support the development of PKCβ inhibitors for the treatment 
of amphetamine-use disorders. 
  In Chapter 2, I fully characterize the effects of enzastaurin, a PKCβ-selective inhibitor, on 
amphetamine-mediated behaviors. Previous studies by Zestos et al. (2016), have shown that 
enzastaurin blocks amphetamine-mediated increases in extracellular dopamine levels. I sought to 
demonstrate that enzastaurin reduces amphetamine-stimulated locomotor activity and show for 
the first time that enzastaurin decreases amphetamine self-administration. In this chapter, the 
effect of enzastaurin on amphetamine-stimulated locomotor activity is characterized across 
different doses of enzastaurin, amphetamine, and pretreatment times. Enzastaurin (10 pmol) 
administered intracerebroventricularly (i.c.v.) shifts the dose-effect curve for amphetamine-
stimulated locomotor activity to the right. More importantly, enzastaurin attenuates the 
reinforcing effects of amphetamine in a self-administration paradigm using an FR5 schedule of 
reinforcement in rats. Interestingly, these effects are only observed following an 18 hr 
pretreatment, and a shorter pretreatment time (3 hr) is not effective at altering amphetamine-
maintained responding. Enzastaurin does not alter responding for sucrose under an FR5 schedule 
of reinforcement, demonstrating that the observed results with amphetamine are not due to 




(10-30 pmol) require an extended period of time to decrease amphetamine-stimulated locomotor 
activity. A large dose of enzastaurin (1 nmol) can acutely decrease amphetamine-stimulated 
locomotor activity. This provides the first hint that PKCβ inhibitors decrease amphetamine-
mediated behaviors through more than one mechanism. Altogether, these results support our 
hypothesis that PKC inhibition decreases amphetamine-mediated behaviors, especially the 
reinforcing effects of amphetamine.  
 In Chapter 3, I assess responding for amphetamine and sucrose under a PR schedule of 
reinforcement, comparing two different PKC inhibitors. Here, I compare responding for 6c 
administered subcutaneously and enzastaurin administered through ICV injections. 6c is a brain-
permeable PKC inhibitor based on the tamoxifen scaffold. We previously demonstrated that 6c 
(s.c.) alters responding for amphetamine under an FR5 schedule of reinforcement 18 hr after 
injection (Carpenter et al. 2017). I find that 18 hr after enzastaurin or 6c pretreatment, the 
breakpoint for amphetamine responding decreases without altering responding for sucrose. A 
larger dose of enzastaurin is required to change responding under a PR schedule compared to the 
previous studies under an FR schedule. These finding further our conclusion that PKC inhibition 
alters the reinforcing properties of drugs and show that PKC inhibition will decrease the 
reinforcing strength of amphetamine.  
 The time course of PKC inhibitor effectiveness has raised the possibility of the inhibitors 
acting through multiple mechanisms to decrease amphetamine-mediated behaviors. In Chapter 4, 
I will discuss data further supporting the existence of multiple mechanisms. I found that if 
ruboxistaurin, another PKCβ-selective inhibitor, is injected into the NAc, a short pretreatment 
(30 min) is enough to decrease locomotor activity, but the effect is gone 18 hr later. Conversely, 




affected following an acute injection but is decreased 18 hr later. A decrease in PKC activity is 
seen in the NAc following an acute injection of a PKCβ inhibitor into the NAc. Following an 18 
hr pretreatment into the VTA, I observe a decrease in levels of PKCβII levels as well as PKC 
activity in the VTA. These findings suggest that PKCβ inhibitors act directly in the NAc to 
decrease amphetamine-mediated behaviors but act indirectly in the VTA, likely by 
downregulating PKCβII.  
 In Chapter 5 of this thesis, I will discuss the implications of these findings and the future 
of PKCβ inhibitors as therapeutics for amphetamine-use disorder. I will also examine additional 
factors that may be involved in the action of the PKC inhibitors. The work presented here will 
provide proof-of-concept work showing that PKCβ inhibitors will decrease amphetamine-
mediated behaviors and the reinforcing effects of amphetamine. Altogether, the findings of this 
thesis strongly support the further development of PKCβ inhibitors as a new therapeutic for 
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Chapter 2 The protein kinase Cβ-selective inhibitor, enzastaurin, attenuates 
amphetamine-stimulated locomotor activity and self-administration 
behaviors in rats 
Abstract 
Pathological amphetamine (AMPH) use is a serious public health concern with no 
pharmacological treatment options. Protein kinase Cβ (PKCβ) has been implicated in the 
mechanism of action of AMPH, such that inhibition of PKCβ attenuates AMPH-stimulated 
dopamine efflux in vivo. With this in mind, inhibition of PKCβ may be a viable therapeutic target 
for AMPH use disorder. The purpose of this study is to demonstrate that selective 
pharmacological inhibition of PKCβ alters AMPH-stimulated behaviors in rats. Rats were 
administered intracerebroventricular (i.c.v.) injections of the PKCβ-selective inhibitor 
enzastaurin 0.5, 3, 6, or 18 hr before evaluating AMPH-stimulated locomotion (0.32-3.2 mg/kg). 
Rats were trained to make responses for different doses of AMPH infusions or sucrose under a 
fixed ratio 5 schedule of reinforcement, and the effects of enzastaurin pretreatment 3 or 18 hr 
prior to a self-administration session were determined. Also, the effect of enzastaurin on AMPH-
stimulated PKC activity in the ventral striatum was evaluated. Low doses of enzastaurin (10-30 
pmol) attenuated AMPH-stimulated locomotor activity and shifted the AMPH dose-effect curve 
to the right following an 18-hr pretreatment. A high dose of enzastaurin (1 nmol) decreased 
AMPH-stimulated locomotor activity 0.5 hr following enzastaurin administration. Rats 




decrease in the number of responses for AMPH, shifted the ascending limb of the amphetamine 
dose effect curve, and produced no change in responses for sucrose. AMPH-stimulated PKC 
activity was decreased following a 0.5 or 18 hr pretreatment, but not a 3 hr pretreatment of 
enzastaurin. These results demonstrate that inhibition of PKCβ decreases AMPH-stimulated 
behaviors and neurobiological changes and suggest that PKCβ is potentially a viable target for 
AMPH use disorder.  
Introduction 
Amphetamines (AMPHs) are a class of stimulants that are highly abused worldwide; this 
class includes amphetamine, methamphetamine, and 3,4-methylenedioxymethamphetamine 
(UNODC 2017). AMPHs are commonly prescribed to children in the form of Adderall for the 
treatment of attention deficit/hyperactivity disorders (Lakhan and Kirchgessner 2012) but are 
also commonly misused for non-medical purposes (Johnston et al. 2016; SAMHSA 2014). Long 
term use of AMPH in patients with attention deficit/hyperactivity disorder has been shown to be 
relatively safe when properly prescribed. However, long term misuse of AMPH may lead to 
cognitive deficits and psychosis (Janowsky and Risch 1979; Lakhan and Kirchgessner 2012; 
Ornstein et al. 2000). Acute effects of AMPH in humans include enhanced attention, alertness, 
and euphoria (Seiden et al. 1993). Similarly, in laboratory animals, small doses of AMPH 
produce increased locomotor activity and sustained attention (Grilly et al. 1989; Randrup et al. 
1963; Wise and Bozarth 1987). Rodents and monkeys will self-administer AMPH, 
demonstrating its ability to act as a reinforcer in animal models (Balster and Schuster 1973; 
Pickens and Harris 1968). Despite the prevalence of AMPH abuse, current treatments are 





AMPHs elicit their rewarding effects in part by increasing extracellular dopamine levels 
in the brain via competition with dopamine for uptake into dopaminergic terminal (e.g., 
dopamine transporter (DAT) substrates). Once in neurons, AMPH reverses the function of DAT, 
evoking a release of dopamine into the synapse, instead of the removal of dopamine from the 
synapse (Seiden et al. 1993). AMPH administration also results in an increase in protein kinase C 
(PKC) activity (Giambalvo 1992). Activation of PKC can lead to increased extracellular 
dopamine levels through exocytosis and/or via DAT (Cowell et al. 2000; Giambalvo 1988). 
Inhibiting PKC in vitro, ex vivo, and in vivo attenuates AMPH-stimulated increases in 
extracellular dopamine levels (Johnson et al. 2005; Kantor and Gnegy 1998; Loweth et al. 2009; 
Zestos et al. 2016).  
Direct injection of PKCβ-selective inhibitors into the nucleus accumbens or genetic 
deletion of PKCβ demonstrated the importance of the β-isomer of PKC in dopamine efflux in 
response to AMPH as well as its effect on AMPH-stimulated locomotor activity (Chen et al. 
2009; Zestos et al. 2016). While there are data demonstrating that PKCβ modulates the 
neurochemical effects of AMPH, whether or not PKCβ inhibition alters the reinforcing effects of 
AMPH is unknown. In this study, we characterized the effects of a PKCβ inhibitor on AMPH-
stimulated behaviors, namely locomotor activity and self-administration in rodents. We found 
that enzastaurin, a PKCβ-selective inhibitor (Faul et al. 2003), effectively decreased AMPH-
stimulated locomotor activity and AMPH-maintained responding in a surmountable manner and 
attenuated PKC activity in the presence of AMPH in the striatum. We believe that these data 
provide proof-of-concept evidence demonstrating the feasibility of selectively targeting PKCβ 





Subjects: Male Sprague-Dawley rats (Harlan Laboratories, Indianapolis, IN) weighing 
approximately 300-350g at the start of the experiments were single-housed in a temperature and 
humidity-controlled environment. Food was available ad libitum; however, rats used in AMPH 
and sucrose self-administration experiments were food restricted to approximately 80-90% of 
their free-feeding weight. All animals were on a 12-hr dark/light cycle with lights on at 0700 and 
all testing was done during the light phase.  All animal procedures were designed within the rules 
and regulations of the National Research Council Guide for the Care and Use of Laboratory 
Animals and approved by the University of Michigan’s Institutional Animal Care and Use 
Committee.  
Drug Solutions and Delivery: D-AMPH (National Institute on Drug Abuse, Bethesda, 
MD) was dissolved in saline and administered subcutaneously (s.c.) for locomotor studies or 
intravenously (i.v.) for self-administration studies. Ketamine (Hospira, Lake Forest, IL) and 
xylazine (Akorn, Lake Forest, IL) were administered intraperitoneally. Enzastaurin was obtained 
from Cayman Chemicals and dissolved in a vehicle solution containing 0.005% dimethyl 
sulfoxide (DMSO) in artificial cerebrospinal fluid (Durect, Cupertino, CA).  
Enzastaurin or vehicle was administered intracerebroventricularly (i.c.v.) via a 
programmable pump that administered 10 µl over 1 hr at a rate of approximately 0.17 µl/min. An 
infusion cannula (2mm C313I, Plastics One, Roanoke, VA) was connected by Tygon tubing to a 
single channel plastic swivel (375/22PS, Instech Laboratories, Plymouth Meeting, PA) 
suspended in a counter-balanced arm (PHM-110-SAI, Med Associates, Fairfax, VT), which was 
attached to a 10 µl Hamilton syringe through Tygon tubing. The rats were awake and in their 





Cannula Implantation: All rats were implanted with a guide cannula (28 gauge with 1.7 
mm projection C313GRL/SPC, Plastics One, Roanoke, VA) to allow for i.c.v. injections. Rats 
were given 5 mg/kg carprofen (s.c.) and ketamine/xylazine (90:10 mg/kg i.p.) and placed in a 
stereotaxic instrument (Kopf Instruments, Tujunga, CA). The cannula was implanted relative to 
bregma (AP = -0.8mm, ML=+1.5mm, DV=-2.8mm (Paxinos and Watson 1998)). The guide 
cannula was held in place with dental cement (OrthoJet-BCA, Lang Dental Manufacturing Co., 
Wheeling, IL) and anchored with two steel screws (19010-10, Fine Science Tools, Foster City, 
CA). The guide cannulae were fitted with dummy cannulae with no extension. Following all 
experiments, cannulae were infused with methylene blue i.c.v. while the rats were under heavy 
anesthesia for 5 min. The rats were decapitated, and brain tissue was collected and examined for 
methylene blue distribution throughout the ventricles.  
Catheter Implantation: For AMPH self-administration studies, rats were also implanted 
with catheters into their left or right femoral vein during a separate surgery. Rats were 
anesthetized with ketamine/xylazine (90:10 mg/kg i.p.) and given 5 mg/kg carprofen (s.c.). 
Catheters made of Micro-Renathane tubing (MRE-040, Braintree Scientific, Braintree, MA) 
were attached to a backmount cannula guide (313-000BM-15-5UP/1/SPC, Plastics One, 
Roanoke, VA) that exited between the scapulae. Rats were allowed to recover for a minimum of 
7 days. The catheters were flushed daily with 0.3-0.5 ml of heparinized-saline (50 U/ml), once 
daily during recovery and twice daily before and after each self-administration session. 
Intracranial cannulae were implanted approximately four weeks after catheter implantation. 
Locomotor Activity: Locomotor activity was measured in an acrylic cage (14” x 14” x 
8”) containing infrared beams spaced 2.54 cm apart (Opto-M3 Activity Monitor). Experimental 




Columbus, OH). Rats received an injection of saline (s.c.) and were habituated to the locomotor 
boxes for 60 min. Following habituation, the rats were given a second injection of saline (s.c.) 
and placed back in the box for 30 min. AMPH (0.32, 1, or 3.2 mg/kg) was then administered 
(s.c.) and activity was recorded for an additional 2.5 hr. The rats were pretreated with 0 (vehicle), 
1, 10, or 30 pmol or 1 nmol enzastaurin i.c.v. in their home cage either 0.5, 3, 6, or 18 hr before 
AMPH administration. The number of beam breaks were recorded every min and summed into 
10 min bins. 
Self-Administration:  
Apparatus: For self-administration studies, rats were placed in operant chambers (ENV-
008CT, Med Associates, St. Albans, VT) inside sound-attenuating chambers (ENV-018CT, Med 
Associates). The operant boxes were outfitted with two nose poke devices each containing a 
yellow light (ENV-114BM), which were located on either side of a pellet receptacle (ENV-
200R7M. Med Associates) attached to a dispenser (ENV-203-45, Med Associates) filled with 45 
mg sucrose pellets. A white house light was on the wall opposite the nose poke devices. Drug 
solutions were delivered via a variable infusion rate syringe pump (PHM-107, Med Associates) 
connected by Tygon tubing to a single channel plastic swivel (375/22PS, Instech Laboratories, 
Plymouth Meeting, PA) on a counter-balanced arm (PHM-110-SAI, Med Associates). The 
Tygon tubing inside the operant chamber was protected with a stainless-steel spring. Data were 
collected using MED-PC Software (SOF-735, Med Associates).  
AMPH Self-Administration: Rats with i.v. catheters were trained to respond in the nose 
poke device for infusions of AMPH (0.1 mg/kg/infusion) on a fixed-ratio 1 (FR1) schedule of 




drug solution to fill the catheters. The “active” nose poke was illuminated by a yellow light and 
responses into the active nose poke were recorded. The light in the “inactive” nose poke was not 
illuminated and responses in the inactive nose poke were recorded but had no scheduled 
consequence. Completion of a FR in the active nose poke resulted in an infusion (100 µl/kg over 
approximately 1 sec) with illumination of the house light. This was followed by a 10 sec 
blackout period during which all stimuli were turned off and responses during the blackout 
period were recorded but had no consequence. Once the animals responded in a consistent 
manner for AMPH infusions, the response requirement was gradually increased to an FR5 and 
the dose of AMPH was decreased to 0.032 mg/kg/infusion. Following stable AMPH self-
administration (less than 20% variation in the number of responses and no increasing or 
decreasing trend in responding over 3 consecutive sessions), saline was repeatedly substituted for 
AMPH for 1-3 consecutive sessions until responding dropped to less than 30% of stable AMPH 
responding levels within a single session. All cues were present during the extinction tests. Once 
responding extinguished in the absence of AMPH, the rats were implanted with cannulae (as 
described above), then responding maintained by AMPH and extinction in the absence of AMPH 
were re-confirmed. The rats were pretreated with 10 pmol enzastaurin or vehicle (i.c.v.) 3 or 18 
hr prior to an AMPH self-administration session.  
A different group of rats were trained to self-administer 0.032 mg/kg/inf AMPH under an 
FR5 schedule of reinforcement as described above. Following stable AMPH self-administration, 
the rats were implanted with intracranial cannulae. Upon re-confirming stable responding for 
AMPH, the rats were switched to a multiple-dose self-administration session. Each daily session 
was comprised of five 25-min components with a 2-min blackout between each component. 




delivered in ascending order by altering the infusion duration: 0 (responding recorded with no 
consequence), 0.0032, 0.01, 0.032, and 0.1 mg/kg/inf AMPH. Following 2-3 consecutive 
sessions of stable responding, saline was substituted for AMPH for all 5 components in one day 
to extinguish responding.  The AMPH dose effect curve was re-established and then the rats 
were pretreated with vehicle or 10 pmol enzastaurin (i.c.v.) 18-hr prior to the self-administration 
session.  
Food Self-Administration: Food self-administration studies were carried out with the 
same design as the AMPH self-administration sessions with a few exceptions. These rats had 
cannulae implanted but no catheters. The sessions lasted for 20 min and completion of a FR 
resulted in the delivery of a single 45 mg sucrose pellet. Instead of saline substitution, 
responding was extinguished by no delivery of the sucrose pellets. All other cues were present 
during the extinction test.  
Protein Kinase C Activity:  
Rats were administered 10 pmol or 1 nmol enzastaurin, or vehicle 0.5, 3, or 18 hr prior to 
an injection of 3 mg/kg AMPH (s.c.). The rats were euthanized 10-30 min following AMPH and 
the ventral striatum was dissected. The tissue was immediately frozen in liquid nitrogen, then 
250 µl boiling 1% SDS was added to each sample. The samples were sonicated for 5 pulses at 
frequency of 20 kHz, amplitude 50% (sonic dismembrator, Fisher Scientific, Pittsburgh, PA) and 
then spun at 14,000 rpm at 4°C, saving the supernatant. The samples (75 µg) were separated by 
SDS-PAGE on a 12% polyacrylamide gel. The proteins were transferred to a nitrocellulose 
membrane at 100 mA for 16 hr. The membranes were blocked in a buffer (5% w/v milk, 150 




associated protein 43 (pGAP43) (Santa Cruz Biotechnology Inc., Santa Cruz, CA) and goat anti-
GAP43 (Santa Cruz Biotechnology) antibodies for 24 hr at 4°C on two separate membranes. 
Primary antibody binding was detected with secondary antibodies for 1 hr at room temperature: 
antibodies for goat anti-rabbit for pGAP43 and donkey anti-goat for total GAP43 (Santa Cruz 
Biotechnology). The antibodies were imaged with Chemiluminescent Western Substrate (EMD 
Millipore, Darmstadt, Germany) and band densities were quantified using Image J software.    
Statistical Analysis: Statistical analyses were performed using GraphPad Prism 7.0 
(GraphPad Software Inc, San Diego, CA). Locomotor activity data are presented as beam breaks 
over time and as the area under the curve (AUC) of beam breaks over time for the first 40 min 
following AMPH administration. Comparisons were made with t-tests, one-way ANOVAs or the 
Kruskal-Wallis test (for nonparametric tests with uneven group size), two-way ANOVAs, and 
three-way ANOVAs, as indicated in the results section and/or figure legends. Alpha level was set 
at 0.05. A Dunnett’s multiple comparison post hoc tests were performed for the dose-effect of 
enzastaurin studies and the time course of the different pretreatment times, Dunn’s multiple 
comparison post hoc tests for the different pretreatment time AUC graph, and Sidak’s multiple 
comparison post hoc tests were used for the locomotor activity time courses following different 
doses of AMPH, AMPH dose-effect curve for locomotor activity, and single-dose self-
administration studies. A Tukeys multiple comparison post hoc test was used for the AMPH 






Figure 2.1 Time- and dose-dependent reduction of AMPH-stimulated locomotion by 
enzastaurin.  
(a) Rats were given vehicle (open circles) or 10 pmol enzastaurin (i.c.v.)  0.5 (closed triangles), 3 
(gray diamonds), 6 (gray triangle), and 18 (closed circles) hr prior to 1 mg/kg AMPH s.c. (n = 6-
7 for all groups except vehicle n = 20). Baseline activity was calculated from the average number 
of beam breaks/10 min following an injection of saline prior to receiving AMPH. Data are 
presented as the number of beam breaks in 10 min bins over time.  * p < 0.05, **** p < 0.0001 
18 hr vs. vehicle pretreatment (b) Rats were given 0 (vehicle-open circles), 1 (closed squares), 10 
(closed circles), or 30 (closed diamonds) pmol of enzastaurin i.c.v. 18 hr prior to 1 mg/kg AMPH 
s.c. (n = 6-7). * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 10 pmol vs. vehicle 
pretreatment, $ p < 0.05, $$ p < 0.01, $$$ p < 0.001 30 pmol vs. vehicle pretreatment (c) 
Locomotor activity over time is summarized as the AUC of beam breaks over time for 40 min 
following AMPH administration for the different pretreatment times. (d) Enzastaurin dose-effect 
summarized as AUC. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 vs vehicle (c, d). 
 
  An 18 hr pretreatment of enzastaurin decreased AMPH-stimulated locomotor activity 
To characterize the effect of PKCβ inhibition on AMPH-stimulated behaviors, we 




course of inhibition by enzastaurin, vehicle or 10 pmol enzastaurin was administered i.c.v. to rats 
0.5, 3, 6, and 18 hr prior to injection of 1 mg/kg AMPH i.p. The data are expressed as the 
number of beam breaks over time (Figure 2.1a) and further summarized as the AUC for beam 
breaks over time (Figure 2.1c). The levels of AMPH-stimulated locomotor activity in vehicle-
pretreated rats did not significantly change with the pretreatment time and were compiled into 
the group labeled vehicle. A two-way ANOVA indicated a significant interaction between the 
enzastaurin pretreatment time and experiment [F (48,492) = 1.79, p = 0.001] and a significant 
main effect of experiment time [F (12,492) = 112.4, p < 0.0001] and enzastaurin pretreatment 
time [F (4,41) = 2.63, p = 0.05] (Figure 2.1a). In data converted to AUC, locomotor activity in 
rats administered enzastaurin 18 hr prior to AMPH was significantly different (p = 0.03) from 
rats pretreated with vehicle, but a 0.5, 3, or 6 hr enzastaurin pretreatment had no effect compared 
to vehicle [Kruskal-Wallis test (p = 0.05)] (Figure 2.1c).  
Different doses of enzastaurin (0-30 pmol) were given to rats i.c.v. 18 hr before 1 mg/kg 
AMPH s.c. The number of beam breaks over time for each dose is shown (Figure 2.1b) and 
further summarized as the AUC for beam breaks over time (Figure 2.1d). There was a significant 
interaction between dose and pretreatment (Figure 2.1b) [two-way ANOVA: F (36,252) = 1.82, 
p=0.005]. As compared with vehicle-treated rats (Figure 2.1d), enzastaurin given 18 hr prior to 
AMPH decreased AMPH-stimulated locomotor activity [one-way ANOVA: F (3,21) = 6.02, p = 





Figure 2.2 A large dose of enzastaurin decreased AMPH-stimulated locomotion.  
 Rats were given vehicle (open hexagons) or 1 nmol enzastaurin (i.c.v.)  (closed hexagons) 0.5 hr 
prior to 1 mg/kg AMPH s.c. (n = 5-6). Baseline activity was calculated from the average number 
of beam breaks/10 min following an injection of saline prior to receiving AMPH. Data are 
presented as the number of beam breaks in 10 min bins over time.  * p < 0.05, ** p < 0.01, *** p 
< 0.001 vehicle vs enzastaurin. 
 
A large dose of enzastaurin decreased AMPH-stimulated locomotor activity acutely 
 Enzastaurin administered directly into the NAc can acutely reduce AMPH-stimulated 
locomotor activity (Zestos et al. 2016) but enzastaurin administered i.c.v. on the pmol level is not 
effective following a short pretreatment. We hypothesized that the concentration of enzastaurin 
i.c.v. was not high enough for an acute effect and, to test this, we performed the experiment using 
a higher dose of enzastaurin. Locomotor activity in rats administered 1 nmol enzastaurin 
following a 30 min pretreatment was significantly decreased compared to vehicle (Figure 2.2). A 
two-way ANOVA demonstrated a significant main effect of time [F (15, 150) = 22.82, p < 
0.0001] and enzastaurin [F (1,10) = 11.42, p = 0.007].  




AMPH-stimulated locomotor activity displays an inverted U-shaped dose-effect curve 
(Rosenzweig-Lipson et al. 1997).  The effect of enzastaurin on locomotor activity produced by 
multiple doses of AMPH was investigated in order to determine potential shifts in the AMPH 
dose-effect curve (Figure 2.3a, b, c, d). These data were further summarized as the AUC of the 
locomotor activity data over time to generate amphetamine dose-effect curves (Figure 2.3e). 
Enzastaurin significantly altered AMPH-stimulated locomotor activity at 1.0 mg/kg AMPH [F 
(15,180) = 2.321, p = 0.0048] (Figure 2.3c) and 3.2 mg/kg AMPH (F (15,150) = 2.341, p = 
0.0049] (Figure 2.3d).  A two-way ANOVA of the dose-effect curve (Figure 2.3e) determined 
that there was a significant interaction between dose of AMPH and enzastaurin pretreatment [F 
(3,42) = 12.05, p < 0.0001]. Enzastaurin did not alter locomotor activity in the absence of 
AMPH. Locomotor activity was significantly decreased at 1 mg/kg AMPH in rats pretreated with 
enzastaurin (p < 0.0001) and significantly increased at 3.2 mg/kg AMPH in rats pretreated with 
enzastaurin (p = 0.006) as compared with vehicle. Overall, enzastaurin appeared to produce a 






Figure 2.3 Enzastaurin pretreatment shifted the dose effect curve of AMPH.  
Rats were pretreated with vehicle (open circles) or 10 pmol enzastaurin (closed circles) i.c.v. 18 
hr prior to AMPH. Locomotor activity was measured for 2 hr following administration of (a) 
saline, (b) 0.32, (c) 1, or (d) 3.2 mg/kg AMPH (s.c.) (n = 6-7 per treatment). Data are presented 
in number of beam breaks in 10 min bins over time. (e) Beam breaks over time were converted 
to AUC following AMPH or saline administration. ** p < 0.01, *** p < 0.001, **** p < 0.0001 




Enzastaurin reduced AMPH-maintained responding without altering responding for 
sucrose  
To determine if a PKCβ inhibitor altered the reinforcing effects of AMPH, we examined 
the effect of enzastaurin on AMPH-maintained responding. Rats were trained to respond for a 
0.032 mg/kg/infusion AMPH on an FR5 schedule of reinforcement and to extinguish responding 
in the absence of AMPH. Following acquisition of responding criteria, pretreatments of vehicle 
or 10 pmol enzastaurin (i.c.v.) were administered 3 and 18 hr prior to a self-administration 
session. Following an 18-hr pretreatment of enzastaurin (Figure 2.4a), the number of responses 
in the active nose poke were decreased by 80% when compared with vehicle pretreatment and 
with stable AMPH-maintained responding in the absence of a pretreatment. A two-way ANOVA 
demonstrated a significant interaction between enzastaurin pretreatment and self-administration 
condition/stage [F (2,18) =8.4, p= 0.003]. In the absence of AMPH, responding significantly 
decreased (p<0.0001). An 18 hr pretreatment of enzastaurin significantly decreased AMPH-
maintained responding as compared with vehicle pretreatment (p<0.001) to levels similar to that 
observed in the absence of AMPH. There were no significant differences in the number of active 
responses following a 3-hr pretreatment of enzastaurin or vehicle as compared with stable 
AMPH-maintained responding (Figure 2.4b). There were no significant differences in inactive 
responses between rats pretreated with enzastaurin or vehicle at 3 or 18 hr prior to the session 





Figure 2.4 Enzastaurin decreased AMPH-maintained responding.  
The figures demonstrate responding maintained by AMPH (0.03 mg/kg/injection) under an FR5 
schedule of reinforcement and during saline substitution (no AMPH). After achieving stable 
responding for AMPH and rapid extinction of responding in the absence of AMPH, separate 
groups of rats were pretreated with vehicle (Veh) or 10 pmol enzastaurin (Enza) either 18 (a) or 
3 (b) hr prior to an AMPH self-administration session. Active responses are shown in the top 
graphs and inactive responses are shown in the bottom graphs. ### p < 0.001 vs. vehicle *** p < 
0.001 and **** p < 0.0001 vs. AMPH alone, $$$$ p< 0.0001 vs. No AMPH (n = 5-6). 
 
 
Figure 2.5 Enzastaurin did not decrease sucrose-maintained responding.  
Figures show responding maintained by sucrose pellets (Food) under an FR5 schedule of 
reinforcement and during the absence of sucrose (No Food). After achieving stable responding 




were pretreated with vehicle (Veh) or 10 pmol enzastaurin (Enza) 18 hr prior to a sucrose self-
administration session. Active responses are shown in the top graph and inactive responses are 
shown in the bottom graph. **** p < 0.0001 vs. Food alone, $$$$ p< 0.0001 vs. No Food. n=5-
6. 
 
In control experiments, rats were trained to respond for sucrose pellets under similar 
conditions to the AMPH self-administration experiments, and we evaluated the effects of 
enzastaurin administered 18 hr prior to a sucrose self-administration session. A two-way 
ANOVA revealed a significant main effect of self-administration condition/stage [F (2,20) 
=125.8, p<0.0001) indicating that responding significantly decreased in the absence of sucrose 
(Figure 2.5). However, there was no significant interaction, demonstrating that enzastaurin 
pretreatment did not significantly alter sucrose-maintained responding as compared with vehicle 
pretreatment. There were also no significant differences in the number of inactive responses in 










(a) Figure shows the number of responses maintained by AMPH under an FR5 schedule of 
reinforcement for three consecutive sessions prior to an enzastaurin (Group1-open squares) or 
vehicle (Group2-open circles) pretreatment. The data show responding over five 25 min 
components, separated by two min between each component. Responding during each 
component results in the delivery of 0, 0.0032, 0.01, 0.032, 0.1 mg/kg/inf AMPH, sequentially. 
(b) Saline was substituted in for AMPH for Group1 (half-filled squares) and Group2 (half-filled 
circles). (c) Group1 was pretreated with 10 pmol enzastaurin (closed squares) and Group2 was 
pretreated with vehicle (closed circles) 18 hr prior to responding for AMPH. **** p < 0.0001 
enzastaurin vs. vehicle. n=6. 
 
As with locomotor activity, the dose-effect curve for AMPH-maintained responding also 
displays an inverted-U shape, making it necessary to assess how enzastaurin alters the AMPH 
dose-effect curve. Two groups of rats were trained to self-administer 0-0.1 mg/kg/inf AMPH 
across five within-session, sequential components (Figure 2.6a, b). The rats were pretreated with 
vehicle or 10 pmol enzastaurin i.c.v. 18 hr prior to the subsequent self-administration session 
(Figure 2.6c). A three-way ANOVA demonstrated a significant interaction between dose, time 
(responding before and after the pretreatment within subject), and enzastaurin/vehicle 
pretreatment [F(4,4) = 7.2, p < 0.0001], and significant interactions between time and 
pretreatment [F(1,4) = 10.6, p = 0.002] and dose and pretreatment [F(4,4) = 4.2, p = 0.004]. 
Responding for 0.01 mg/kg/inf AMPH was significantly decreased in enzastaurin-treated rats 
compared to vehicle (p < 0.0001) and compared to levels of responding prior to the pretreatment 
(p < 0.0001). The peak level of responding in rats pretreated with enzastaurin was significantly 
different before and after the enzastaurin pretreatment (p = 0.002). These results indicate that 
enzastaurin pretreatment results in a rightward and downward shift the dose-effect curve for 





Figure 2.7 A 30 min and 18-hr, but not a 3-hr, pretreatment with enzastaurin decreased 
PKC activity in the ventral striatum of AMPH-treated rats. 
 Levels of phosphoser41GAP43 (pGAP43) over total GAP43 (tGAP43) are shown in the ventral 
striatal tissue of AMPH-treated rats given vehicle/enzastaurin (10 pmol or 1 nmol) 30 min (a), 3 
hr (b), or 18 hr (c) prior to collecting the tissue.  Data are presented as O.D. pGAP43 / tGAP 43 
(% vehicle). * p < 0.05, ** p < 0.01 vehicle vs. enzastaurin. n=6-7. 
 
Enzastaurin decreased PKC activity in AMPH-treated rats 
We wanted to determine if PKC activity was altered at time points corresponding to the 
enzastaurin-induced changes in AMPH-stimulated locomotor activity and responding for AMPH. 
Rats were pretreated with vehicle, 10 pmol, or 1 nmol enzastaurin (i.c.v.) at 0.5, 3 or 18 hr prior 
to receiving AMPH s.c. (Figure 2.7). PKC activity was determined by phosphorylation of 
GAP43 at serine41 (pGAP43), a substrate site selective for PKC (Oehrlein et a. 1996). pGAP43 
levels were significantly decreased following 10 pmol by more than 40% and 1 nmol enzastaurin 
by more than 50% compared to vehicle [one-way ANOVA: F (2,17) = 7.44, p = 0.005] (Figure 
2.7a). pGAP43 was decreased by over 50% in AMPH-treated rats following an 18-hr 
pretreatment of 10 pmol enzastaurin as compared with vehicle pretreatment (Figure 2.7b) [t-test: 




pretreatment of 10 pmol enzastaurin as compared with vehicle (Figure 2.7c). Enzastaurin did not 
alter total levels of GAP43 in the striatum.  
Discussion 
A role for PKCβ in the behavioral effects of AMPH has been demonstrated using PKC 
inhibitors in rats (Browman et al. 1998; Carpenter et al. 2017; Zestos et al. 2016) and genetic 
deletion of PKCβ in mice (Chen et al. 2009). In this study, we sought to establish the 
consequences of selective inhibition of the PKCβ isoform on the reinforcing effects of AMPH. A 
highly soluble, brain permeable PKCβ inhibitor would be an ideal tool, however due to a dearth 
of such drugs, we chose to administer enzastaurin centrally (i.c.v.) to evaluate its effects on 
amphetamine-induced locomotor activity, amphetamine-maintained behavior, and to take note of 
any adverse events. We performed an investigation of dose and time dependence of PKCβ 
inhibition on AMPH-stimulated locomotor activity and found that an 18-hr pretreatment of 10 
pmol enzastaurin i.c.v. was most effective. We then demonstrated that this same dose of 
enzastaurin decreased AMPH self-administration without generally suppressing behavior. All 
together, we have shown pharmacological inhibition of PKCβ is effective at decreasing AMPH-
stimulated behaviors.  
First, we showed that pharmacological inhibition of PKCβ produced a rightward shift in 
the AMPH dose effect curve without altering baseline locomotor activity. Vehicle-pretreated rats 
displayed the typical inverted-U shaped AMPH dose-effect curve typically seen in adult rats 
(Campbell et al. 1969). At the measured times, 10 pmol enzastaurin i.c.v. was only effective at 
decreasing AMPH-stimulated locomotor activity 18 hr following administration. Notably, the 
normal inverted U-shaped dose effect curve was not evident in enzastaurin-treated rats. Increased 




levels of stereotypy in the enzastaurin-treated rats (Del Rio and Fuentes 1969). A higher dose of 
AMPH might reveal the inverted U-shaped curve. These results suggest that 10 pmol enzastaurin 
shifts the dose-effect curve of AMPH-stimulated locomotor activity to the right, consistent with 
data from PKCβ deletion or inhibition (Chen et al. 2009).  
We previously showed that a novel non-selective PKC inhibitor decreased AMPH-
maintained responding in rats (Carpenter et al. 2017). The present study demonstrated for the 
first time that the selective PKCβ inhibitor enzastaurin, at a dose that reduced AMPH-stimulated 
locomotor behavior, decreased the reinforcing effects of AMPH without altering responding for 
non-drug rewards. Enzastaurin decreased AMPH-maintained responding to levels observed with 
saline substitution. An 18-hr pretreatment of enzastaurin did not alter sucrose-maintained 
responding in a separate group of rats. We evaluated the dose-effect curve for AMPH-maintained 
responding under an FR5 schedule of reinforcement and found that enzastaurin shifted the 
ascending limb of the curve to the right without increasing AMPH intake on the descending 
limb. These findings strongly support the hypothesis that inhibition of PKCβ reduces AMPH-
mediated behaviors and reinforcing effects without altering sucrose-maintained responding.  
We initially observed that an 18 hr pretreatment with enzastaurin decreased responding 
for AMPH, possibly indicating that enzastaurin decreased the reinforcing effects of AMPH. To 
further probe this interpretation, we evaluated the effects of enzastaurin on an AMPH dose-effect 
curve determined within session. Similar to that observed in the locomotion experiments, the 
ability of enzastaurin to decrease AMPH-maintained behavior was surmountable. This was not a 
parallel rightward shift in the amphetamine dose-effect curve but more a shift in the ascending 
limb. This complex shift in the AMPH dose-effect curve may be due to the within session 




the shift in the AMPH dose-effect curve may be due to the complex interaction between the site 
of action of AMPH and PKCβ. Few studies have evaluated or characterized shifts in drug dose-
effect curves following inhibition of one component of the intracellular signaling pathway. These 
interactions are likely to be multifaceted and potentially dose-dependent. For example, small 
doses of AMPH may be more dependent on PKCβ signaling mechanisms, whereas large AMPH 
doses may invoke multiple signaling molecules, cellular actions, and neurocircuits overwhelming 
the effects of PKCβ. However, future studies would need to explore these effects and shifts in the 
AMPH dose effect curve in more detail.   
A possible alternative explanation for the effect of PKCβ inhibition on the reinforcing 
effects of AMPH is through the impairment of memory. PKCβ is important for memory through 
its role in promoting LTP (Colley and Routtenberg 1993; Lovinger et al. 1986; Nogues 1997; 
Routtenberg et al. 1986; Weeber et al. 2000), and pharmacological inhibition of PKC can cause 
memory impairment, especially with drug-associated memories (Aujla and Beninger 2003; 
Cervo et al. 1997; Takashima et al. 1991). This raises the possibility that decreased responding 
for AMPH in the presence of enzastaurin may be due to impairment of memories associated with 
self-administration training (e.g., operation of the nose poke device and/or reinforcer 
contingencies). However, we did not observe alterations in responding for sucrose under similar 
experimental conditions, suggesting that we are not impairing memory retrieval under these 
experimental conditions.  
Our data repeatedly demonstrated that low doses of enzastaurin, given i.c.v., must be 
given a substantially long time before AMPH to observe an effect on AMPH-mediated 
behaviors. In contrast to our current results with i.c.v. enzastaurin administration, previous 




directly into the nucleus accumbens (Browman et al. 1998; Loweth et al. 2009; Zestos et al. 
2016). One possible explanation for the lack of immediate drug effect in this study could be due 
to low levels of enzastaurin in the nucleus accumbens following i.c.v. administration. Although 
the administered concentrations of enzastaurin are calculated to be similar, the direct application 
of concentrated drug in the nucleus accumbens (Zestos et al. 2016) might produce more 
immediate effects as compared with the slower diffusion of the drug when given i.c.v.  (Luger et 
al. 2005). To test this, we administered a large dose of enzastaurin (1 nmol) 30 min prior to 
AMPH administration and saw a decrease in locomotor activity. An injection of 10 pmol 
enzastaurin at the same timepoint did not affect AMPH-stimulated locomotor activity. This 
raises the possibility that different mechanisms may be behind the decrease in AMPH-mediated 
behaviors observed at 18 hr and acutely.  
In order to take a closer look at drug action following the different pretreatment times, we 
looked at PKC activity following enzastaurin administration. Previous studies demonstrated that 
AMPH increases phosphorylation of GAP43, a substrate of PKC, in rat striatal tissue and that 
PKC inhibitors block this effect (Iwata et al. 1997a, Iwata et al. 1997b). We used AMPH-
stimulated GAP43 phosphorylation as a readout of PKC activity to determine how long and short 
pretreatments of enzastaurin effect PKC activity. Although most PKC isozymes will 
phosphorylate GAP43, phosphorylation of the protein is especially robust with PKCβ (Oehrlein 
et al. 1996, Sheu et al. 1990, Young et al. 2002). While it might be assumed that a PKC inhibitor 
would inhibit all substrates of PKC equally, that is not necessarily true (Carpenter et al. 2017). 
Because GAP-43 is readily phosphorylated in response to AMPH treatment both in vivo and in 
vitro (Iwata et al. 1997a, Iwata et al. 1997b), inhibition of AMPH-stimulated PKC activity may 




We found that AMPH-stimulated PKC phosphorylation of GAP43 is decreased by i.c.v. 
enzastaurin administration following a 30 min pretreatment and an 18 hr pretreatment, but not 
following a 3 hr pretreatment. One thing to note is that, while 30 min pretreatment of 10 pmol 
enzastaurin decreased PKC activity in the ventral striatum, it has no effect on amphetamine-
stimulated locomotor activity. There are a couple possible explanations for these unusual results. 
First, PKCβ inhibition alone may not be sufficient to decrease amphetamine-stimulated 
locomotor activity or that 10 pmol enzastaurin does not produce a robust decrease in PKCβ to 
have an effect on behavior. Although the 10 pmol enzastaurin statistically decreased 
phosphorylation of GAP43, the effect was quite variable, suggesting that the effect is not robust 
or that the assay is not sensitive enough to differentiate fine changes in PKC activity. Second, it 
is also possible that PKCβ inhibition in the nucleus accumbens is necessary, but not sufficient, to 
decrease amphetamine-stimulated behaviors. Locomotor activity is regulated by neurocircuitry 
on many levels and the ventral striatum is only a small snapshot of the brain, therefore the 
actions of large and small doses of enzastaurin in in the nucleus and/or other brain regions may 
be important for modulating locomotor activity.  
Another conundrum raised by these data is the question of why PKCβ inhibitors act 18 hr 
after administration. Enzastaurin decreased PKC activity 18 hr, but not 3 hr after administration. 
These finding support the earlier point that PKC inhibitors may decrease AMPH-mediated 
behaviors through a secondary mechanism. As inhibition of PKC activity is again evident at a 
later timepoint, it is possible that the mechanism underlying the long pretreatment effect is due to 
changes downstream of PKC signaling that ultimately affect PKC activity. Some groups have 




PKCβ mRNA levels, which is one possible explanation for a PKC inhibitor’s secondary effect on 
AMPH-mediated behaviors (Liu et al. 2004).   
Another explanation for time course of enzastaurin could be due to its metabolism and 
potential active metabolites. Human studies indicated enzastaurin has long-lasting, active 
metabolites (Carducci et al. 2006). Multiple-dose pharmacokinetic studies in Fischer 344 rats 
following oral administration found the half-life of enzastaurin to be around 2 hr and the half-life 
of its active metabolite to be 3.6 hr with the lowest dose tested. The half-life increased with dose, 
possibly due to metabolic capacity (personal communications with Denovo Biopharma and Eli 
Lilly). However, as another structurally unrelated PKC inhibitor also displays a similar time 
course (Carpenter et al. 2017), we believe that the time course is more related to the mechanism 
of action of these drugs and not their pharmacokinetics.  
Taken together, our results show that PKCβ inhibition may be a viable therapeutic option 
to treat AMPH abuse. A major concern in developing a PKCβ inhibitor as a therapeutic is 
potential toxic effects due to the ubiquitous nature of PKC. However, clinical studies with 
enzastaurin and other PKCβ inhibitors demonstrated good profiles (Vinik et al. 2005; Welch et 
al. 2007) and our own studies have shown that enzastaurin does not suppress generally elicited or 
conditioned behaviors. Other isozymes of PKC may be compensating for the reduction in PKCβ 
activity in ways that lessen the impact and toxicity.   
While we have shown that enzastaurin decreased AMPH-taking behaviors, we did not 
test for the effect it would have on AMPH-seeking behaviors and motivation for AMPH. Future 
work will utilize reinstatement procedures and progressive ratio schedules of reinforcement to 
further evaluate the behavioral effects PKCβ inhibition. More work will also need to be done to 




assess the effect of PKCβ inhibition on AMPH sensitization, additional schedules of 
reinforcement, and extended-access self-administration will also be useful in assessing PKCβ 
inhibitors as potential therapeutics. In conclusion, the present findings provide proof-of-concept 
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Chapter 3 PKC inhibition decreases responding for amphetamine under a 
progressive-ratio schedule of reinforcement 
Abstract  
Amphetamine (AMPH) are a class of stimulants that are widely misused. They can act in 
the brain disrupting dopamine regulation in the brain, resulting in an increase in extracellular 
dopamine levels. Protein kinase C (PKC) has been shown to be important for these actions; 
inhibiting PKC can block increases in AMPH-stimulated extracellular dopamine levels. 
Inhibition of PKC can also attenuate certain behavioral effects of AMPH such as AMPH-
stimulated locomotor activity. In this study, we wish to examine whether PKC inhibition can 
alter the reinforcing properties of AMPH. Male Sprague-Dawley rats were trained to self-
administer 0.032 mg/kg/infusion AMPH or sucrose pellets under a progressive-ratio (PR) 
schedule of reinforcement. Number of infusions earned, breakpoints, and session duration were 
recorded over consecutive sessions. Once AMPH-maintained responding stabilized, rats were 
pretreated with 0, 10, or 30 pmol of enzastaurin, a PKCβ-selective inhibitor, or 6 mg/kg 6c, a 
brain-permeable PKC inhibitor, 18 hr prior to a self-administration session. A pretreatment of 30 
pmol enzastaurin or 6 mg/kg 6c decreased the number of AMPH infusions earned and 
breakpoints without altering sucrose-maintained behaviors. These data suggest that PKC 
inhibition can selectively alter the reinforcing properties of AMPH and are worth pursuing as 






Amphetamines (AMPH) are a class of stimulants that are commonly prescribed for the 
treatment of attention deficit/hyperactivity disorder (Lakhan and Kirchgessner 2012). They are 
also among the most highly abused classes of drugs in the world and present a serious public 
health risk (McCabe et al. 2017; SAMHA 2014; UNODC 2010). Furthermore, nearly one in ten 
people who misuse amphetamines during adolescence later develop substance-use disorders  
(Compton et al. 2018). There are currently no approved pharmacological interventions for 
treating AMPH-use disorder.  
AMPHs can act by dysregulating dopamine levels in the brain; they enter dopaminergic 
neurons through the dopamine transporter (DAT) and reverse the function of DAT, resulting in a 
release of dopamine from the neuron into the synapse (Seiden et al. 1993). Protein kinase C 
(PKC), a common signaling protein, has been shown to play a role in AMPH action. AMPH 
administration can activate PKC (Giambalvo 1992; Iwata et al. 1997) and PKC activation can 
further increase AMPH-induced dopamine release into the synapse (Cowell et al. 2000; 
Giambalvo 1988). Conversely, inhibition of PKC blunts an increase in AMPH-stimulated 
extracellular dopamine levels ex vivo and in vivo (Johnson et al. 2005; Zestos et al. 2016). 
Furthermore, pharmacological inhibition of PKC can decrease AMPH-stimulated locomotor 
activity (Browman et al. 1998; Carpenter et al. 2017; Zestos et al. 2016). Additional studies have 
indicated β isoform of PKC to be particularly important for the action of AMPH (Chen et al. 
2009; Johnson et al. 2005). 
Our studies have demonstrated that pharmacological inhibition of PKCβ can reduce 
AMPH-stimulated locomotor activity as well as ongoing AMPH self-administration under a 




shown a novel brain-permeable, non-selective PKC inhibitor, 6c, can decrease responding for 
AMPH under an FR ratio, also after an 18-hr pretreatment (Carpenter et al. 2017). While an FR 
schedule of reinforcement is a simple measure of drug-taking behavior and can be the first step 
in screening the effectiveness of a novel therapeutic, other schedules of reinforcement can 
provide additional information. A progressive-ratio (PR) schedule of reinforcement increases the 
ratio of responses required for the delivery of a reinforcer; response ratios can increase within or 
between self-administration sessions. One output of a PR session is the breakpoint: the final ratio 
completed in the session (Hodos 1961). A PR schedule of reinforcement is thought to evaluate 
quantitatively the reinforcing strength of drugs of abuse (Hodos 1961; Richardson and Roberts 
1996). Thus, looking at the effect of these drugs on AMPH self-administration under a PR 
schedule of reinforcement can measure whether a PKC inhibitor affects the reinforcing strength 
of AMPH. 
In this study, we investigated whether or not the PKCβ inhibitor, enzastaurin, or the 
general PKC inhibitor, 6c, would alter responding for AMPH under a PR schedule of 
reinforcement. We pursued this goal to determine if PKC inhibition alters the motivation for and 
the reinforcing strength of AMPH, with the long-term goal of developing a therapeutic for 
AMPH-use disorder. We found that enzastaurin and 6c decreased the breakpoint for AMPH self-
administration compared to vehicle, without affecting the breakpoint for sucrose self-
administration. These data suggest that PKC inhibition decreases the reinforcing efficacy of 
AMPH.   
Methods 
Subjects: Male Sprague-Dawley rats (Envigo Laboratories, Indianapolis, IN) were 




restricted to 80-90% of their body weight. The rats were on a 12-hr light/dark cycle with lights 
on at 0700 and all testing was done during the light phase. The animal procedures were designed 
within the rules and regulations of the National Research Council Guide for the Care and Use of 
Laboratory Animals and approved by the University of Michigan Institutional Animal Case and 
Use Committee.  
Drugs and solutions: d-AMPH was dissolved in saline and administered intravenously. 
Artificial cerebral spinal fluid (aCSF) was prepared according to a recipe produced by ALZET 
Osmotic Pumps (Durect Corporation, Cupertino, CA). Enzastaurin (Cayman Chemical, Ann 
Arbor, MI) was dissolved in a vehicle solution containing 0.005% dimethyl sulfoxide in aCSF 
and administered (i.c.v.). 6c (6c·2.5 HCl) was synthesized by the Vahlteich Medicinal Chemistry 
Core at the University of Michigan and dissolved in a solution containing 5% Tween-80 in saline 
and administered s.c.  
Catheter Implantation: Rats were implanted with intravenous catheters into their left or 
right femoral vein. They were first anesthetized with ketamine (90 mg/kg) and xylazine (10 
mg/kg) i.p. and administered 5 mg/kg carprofen s.c. Catheters were prepared in-house from 
Micro-Renathane tubing (MRE-040, Braintree Scientific, Braintree, MA) with a Tygon tubing 
(ND 100-80, Saint-Gobain, Malvern, PA) sleeve. The catheters exited between the scapulae and 
were attached to a backmount cannula guide (313-0090BM-15-5UP/1/SPC, Plastics One, 
Roanoke, VA). Rats were flushed with 0.3-0.5 ml of heparinized saline (50 U/ml) before and 
after each self-administration session.  
Cannula Implantation: Rats administered enzastaurin were implanted with a guide 
cannula to allow for direct injections into their lateral ventricles (i.c.v.). The rats were 




instrument (Kopf Instruments, Tujunga, CA). The guide cannula (28 gauge with 1.7 mm 
projection C313GRL/SPC, Plastics One, Roanoke, VA) was implanted at AP = -0.8 mm, ML = 
1.5 mm, DV = -2.8 mm relative to bregma (Paxinos and Watson 1998) and held in place with 
dental cement (OrthoJet-BCA, Lang Dental Manufacturing Co., Wheeling, IL) and two anchor 
screws (19010-10, Fine Science Tools, Foster City, CA). Placement of the guide cannula was 
verified following completion of the experiments by infusing methylene blue dye into the guide 
cannula and examining the brain for dye distribution in both sides of the lateral ventricles and the 
third and fourth ventricles.  
Self-Administration Apparatus: In the self-administration studies, operant chambers 
(ENV-008CT, Med Associates, St. Albans, VT) in sound-attenuating cubicles (ENV-018CT, 
Med Associates) were used. Chambers had two nose poke devices (ENV-114BM, Med 
Associates) on either side of a pellet receptacle (ENV-200R7M, Med Associates) and a white 
house light on the opposite wall. Data were recorded using MED-PC Software (SOF-735, Med 
Associates). Reinforcers were delivered through a dispenser for sucrose pellets (ENV-203-45, 
Med Associates) or a variable infusion rate syringe pump for AMPH (PHM-107, Med 
Associates). The syringe pump was connected to Tygon tubing by a single channel, plastic 
swivel (375/22PS, Instech Laboratories, Plymouth Meeting, PA) held in place by a counter-
balanced arm (PHM-110-SAI, Med Associates).  
AMPH Self-Administration: The rats were trained to respond in the nose poke devices 
for intravenous infusions of AMPH (0.1 mg/kg/infusion) on an FR 1 schedule of reinforcement 
during daily 60 min sessions. Sessions began with an infusion of 0.5 ml of AMPH to prefill the 
catheter and illumination of a single nose poke device only (active nose poke). Responding in the 




poke light, and illumination of the house light, followed by a 10 sec blackout period in which 
responses were recorded but had no consequence. Responses in the inactive nose poke (not 
illuminated) were recorded but had no scheduled consequence. Once the rats reliably responded 
for more than 20 infusions per session, the AMPH dose was decreased to 0.032 mg/kg/infusion. 
Some rats were implanted with cannulas. After recovery from surgery, the rats continued daily 
AMPH self-administration sessions under an FR1 schedule until consistent responding was 
stable. Once this was achieved, both groups began training under a PR schedule, in which the 
response requirement for a single infusion increases in an exponential manner as described in 
Robert and Richardson (1992). Self-administration sessions under the PR schedule of 
reinforcement could last 180 min but was terminated if a rat did not complete a ratio within 30 
min. The final ratio completed is referred to as the breakpoint (Roberts and Goeders 1989). The 
number of responses, the number of reinforcers, session duration, and the breakpoint were 
recorded at the end of each sessions. Stable responding was determined as a change in one or less 
infusions between sessions. Once stable responding was achieved, cannulated rats were given 
vehicle (aCSF), 10, or 30 pmol of enzastaurin (i.c.v.), and the non-cannulated rats were given 
vehicle (5% Tween-80 in saline) or 6 mg/kg 6c (s.c.) 18 hr prior to a test session. During the test 
sessions, rats responded for AMPH infusions under a PR schedule as usual and all cues remained 
present. In a separate group of rats, vehicle pretreatments (i.c.v.) were administered and saline 
was substituted for AMPH for a single session to determine breakpoints for AMPH-paired cues 
alone in the absence of AMPH. After a single test session, AMPH-maintained responding was 
evaluated for an additional 4 days. 
Sucrose Self-Administration: The sucrose self-administration studies were carried out 




response requirement resulted in the delivery of a 45 mg sucrose pellet. The training sessions 
under an FR schedule of reinforcement lasted for 20 min, but the sessions under a PR schedule 
could last for 180 min and were terminated if a ratio was not completed in 30 min. On the testing 
days, rats were pretreated with vehicle or 30 pmol enzastaurin (i.c.v.) 18 hr prior to a test session 
where responding resulted in the delivery of a sucrose pellet or the conditioned stimuli alone.   
Statistics: Data were analyzed, and statistical analyses were perform using GraphPad 
Prism 8.0 (GraphPad Software Inc., San Diego, CA). Comparisons were made with unpaired t-
tests, one-way ANOVAs, and two-way ANOVAs as indicated in the results section. Post hoc 
analyses were completed with Sidak’s multiple comparisons test and Tukey’s multiple 
comparisons test. 
Results 
Enzastaurin decreased responding for AMPH but not sucrose under a PR schedule of 
reinforcement 
We evaluated whether or not the PKCβ-selective inhibitor, enzastaurin, altered AMPH-
maintained responding under a PR schedule of reinforcement. Figure 3.1 shows data collected 
from the 3 sessions prior to a test session in which responding under the PR schedule was 
evaluated 18 hr following a pretreatment with vehicle, 10, or 30 pmol enzastaurin. A two-way 
ANOVA comparing pretreatments across the self-administration sessions (Figure 3.1a) 
demonstrated a significant interaction between pretreatment and session [F (9, 60) = 3.803, p = 
0.0008] and a significant main effect of session [F (3, 60) = 21.46, p < 0.0001]. Post hoc 
analyses comparing across the different groups demonstrated no significant difference in the 
number of infusions during sessions 1-3, but a significant decrease in the number of infusions 




pretreatments (Tukey’s multiple comparisons test p = 0.004, .03 respectively). In one group of 
rats pretreated with vehicle, saline was substituted for AMPH to evaluate responding for AMPH-
paired cues in the absence of AMPH. Under these conditions, the number of infusions earned 
decreased by approximately 50% as compared with infusions earned when AMPH was available 
(statistically different from sessions 1-3 (Tukey’s multiple comparisons test p < 0.0001)). 
Responding for saline infusions was not statistically different from responding for AMPH 
following pretreatment with 30 pmol enzastaurin.  A pretreatment with 10 pmol enzastaurin 
resulted in little change to the number of infusions of AMPH earned.  A one-way ANOVA 
looking at the number of infusions alone (Figure 3.1b) showed a significant effect of 
pretreatment [F (3, 20) = 4.558, p = 0.0137] with the vehicle + saline group and the 30 pmol 
pretreatment group being significantly different from vehicle + AMPH (Sidak’s multiple 
comparisons test p = 0.03 for both).  
 
Figure 3.1 Enzastaurin decreased responding for AMPH under a PR schedule of 
reinforcement. 
 (a) demonstrates the number of infusions earned (left axis) and the final ratio completed (right 
axis) during the test day (session 4) and the three consecutive sessions prior to the test day. aCSF 
(i.c.v.) was given to the rats18 hr prior to responding for AMPH (open squares) or saline (open 




(i.c.v.) 18 hr prior responding for AMPH. The test day data are further summarized in a bar 
graph (b) showing individual data. * p < 0.05 vehicle + saline/30 pmol enzastaurin vs vehicle + 
AMPH (a, b)/10 pmol enzastaurin (a). n=6. 
 
 
Figure 3.2 Enzastaurin did not alter responding for sucrose under a PR schedule of 
reinforcement  
(a) demonstrates the number of sucrose pellets earned (left axis) and the final ratio completed 
(right axis) during the test day (session 4) and the three consecutive sessions prior to the test day 
(sessions 1-3). Rats were given aCSF (i.c.v.) 18 hr prior to responding for sucrose pellets (open 
circles) or responding for sucrose cues alone (open squares) or they were administered 30 pmol 
(closed triangles) of enzastaurin (i.c.v.) 18 hr prior responding for sucrose. The test day data are 
further summarized in a bar graph (b) showing the individual data. ** p < 0.01, **** p < 0.0001 
vehicle + no sucrose vs. vehicle + sucrose (a, b)/30 pmol enzastaurin (a). n=6. 
 
To determine if this dose of enzastaurin would decrease any operant behavior, rats were 
trained to self-administer sucrose pellets under a progressive ratio schedule of reinforcement 
before a pretreatment with vehicle or enzastaurin (Figure 3.2). A repeated measure across time 
two-way ANOVA showed a significant interaction of pretreatment and session [F (6,45) = 14.04, 
p < 0.0001] with a significant main effect of session [F (3, 45) = 18.99, p < 0.0001]. Responding 
in the absence of a reinforcer was decreased compared with responding for sucrose regardless of 




pmol enzastaurin did not significantly affect the number of sucrose pellets earned compared to 
vehicle. A one-way ANOVA comparing the test day alone (Figure 3.2b) showed a significant 
effect of pretreatment [F (2, 15) = 12.19, p = 0.0007] with the vehicle + no sucrose being 
significantly different from vehicle + sucrose and 30 pmol enzastaurin + sucrose (p = 0.001, 
0.002 respectively).  
 
 
Figure 3.3 The brain permeable PKC inhibitor 6c decreased responding for AMPH under 
a PR schedule of reinforcement.  
The graph demonstrates number of infusions earned (left axis) and the final ratio completed 
(right axis) during the test day (session 4) and the three consecutive sessions prior to the test day 
(a). Rats were administered 6c (s.c.) or vehicle 18 hr prior to self-administering AMPH. The test 
day data are further summarized in a bar graph (b) showing the individual data. *** p < 0.001, 
**** p < 0.0001 vehicle vs 6c. n=6. 
 
 
6c decreased responding for AMPH under a PR schedule of reinforcement 
Previous data demonstrated that the nonselective, brain penetrant PKC inhibitor 6c can 
decrease AMPH self-administration under an FR schedule of reinforcement (Carpenter et al. 
2017), thus we sought to determine the effects of 6c on AMPH-maintained responding under a 




reinforcement were given vehicle or 6 mg/kg 6c (s.c.); data from the three sessions prior to the 
test and the test session are shown in Figure 3.3a. An injection of 6c significantly decreased 
responding for AMPH under a PR schedule of reinforcement (repeated measures by session two-
way ANOVA [F (3, 30) = 21.42, p < 0.0001] with a significant main effect of session [F (3, 30) 
= 11.26, p < 0.0001]). Sidak’s post hoc analysis showed 6c significantly decreased the number of 
responses on the test day compared to the vehicle pretreatment on the test session (p < 0.0001) 
and compared to responding during sessions 1-3 (p < 0.0001). A t-test comparing the number of 
infusions earned on the test day alone (Figure 3.3b) showed a significant decrease in infusions (p 
= 0.0006). There was no significant change in the number of infusions earned during sessions 1-
3 between the two groups of rats.  
Discussion 
Previously it was shown that these PKC inhibitors can decrease ongoing AMPH self-
administration under an FR schedule of reinforcement (Carpenter et al. 2017). In this study, we 
sought to evaluate further the effects of PKC inhibitors on AMPH-maintained behaviors under a 
different schedule of reinforcement. Our findings show for the first time that the PKCβ-selective 
inhibitor enzastaurin and the brain-permeable PKC inhibitor 6c can alter responding for AMPH 
under a PR schedule of reinforcement without altering responding for other reinforcers (sucrose). 
Rats pretreated with enzastaurin or 6c earned less infusions and had a lower breakpoint for 
AMPH compared with their previous levels of AMPH-maintained responding and compared 
with rats that received vehicle pretreatments. This suggests that PKC inhibition may change the 
reinforcing strength of AMPH and/or the motivation to work for AMPH infusions (Hodos 1961; 




One notable finding is that the dose of enzastaurin previously shown to be effective at 
decreasing AMPH-stimulated locomotor activity and self-administration under an FR schedule, 
10 pmol enzastaurin, is not effective at altering the breakpoint under a PR schedule. The PR 
schedule is considered a higher effort task than responding under an FR schedule, so it is 
possible that higher doses of enzastaurin are necessary to alter those behaviors. Another 
interesting note is that both enzastaurin and 6c can alter AMPH-maintained responding following 
a long pretreatment time, regardless of their route of administration. This is consistent with our 
previous studies demonstrating that an 18 hr pretreatment of enzastaurin or 6c is required to 
decrease AMPH self-administration (Carpenter et al. 2017). While little is known about the 
pharmacokinetics of 6c, microdialysis studies have demonstrated that 6c is present in minimal 
concentrations in the nucleus accumbens following administration of the drug (Carpenter et al. 
2017). Furthermore, the half-life of enzastaurin following oral administration is 2 hr (personal 
communications with Denovo Biopharma and Eli Lilly). While these studies have not been 
repeated following i.c.v. administration, it is unlikely that metabolism will drastically differ 
between oral and i.c.v. administration. The possibility of a metabolite being responsible for the 
long-lasting effects of either drug cannot be ruled out, but due to the differences in structures and 
routes of administration. This could indicate a second mechanism, indirectly due to or unrelated 
to direct PKC inhibition, is responsible for decreasing AMPH self-administration. 
One concern about a within session design for measuring breakpoint is the amount of 
AMPH consumed could affect responding for the breakpoint. We do not believe this is a major 
concern here as the number of infusions earned is less than half of the infusions typically earned 
when the animals self-administered AMPH under an FR schedule. Another limit of this study is 




our previous findings, we highly expect that enzastaurin would shift the dose-effect curve for 
AMPH self-administration under a PR schedule down and to the right as it does in Chapter 2.   
 Altogether, these studies demonstrate two structurally different PKC inhibitors previously 
shown to decrease AMPH self-administration under an FR schedule of reinforcement also 
decrease self-administration under a PR schedule of reinforcement. These findings suggest that 
PKC inhibition may be decreasing the reinforcing strength of AMPH in rats or the motivation to 
work for AMPH infusions. As these drugs do not decrease responding for sucrose, this suggests 
that the doses tested are not inhibiting general behavior and may be somewhat selective for 
AMPH. Future studies will evaluate the effect of PKC inhibition on additional doses of AMPH, 
other drugs of abuse, and other models of drug seeking behaviors such as the 
extinction/reinstatement paradigm. These findings are a promising step towards the development 
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Chapter 4 PKC inhibition attenuates amphetamine-stimulated locomotor 
activity through a direct and indirect mechanism 
Abstract 
 Protein kinase Cβ (PKCβ) inhibitors have been shown to decrease the behavioral effects 
of amphetamine (AMPH). Previous studies demonstrated that a PKCβ inhibitor acutely 
decreased AMPH-stimulated locomotor activity when injected into the nucleus accumbens 
(NAc), but the same dose (10 pmol) injected into the ventricles only decreased locomotor 
activity 18 hr after administration. From these studies, we hypothesized that PKCβ inhibitors act 
to decrease AMPH-stimulated locomotor activity directly in the NAc and indirectly in a different 
brain region. To test this hypothesis, rats were implanted with cannulas to allow for direct 
injections into the NAc or the VTA. They were pretreated with 10 pmol ruboxistaurin 30 min or 
18 hr before receiving 1 mg/kg AMPH and recording locomotor activity. PKCβ levels and 
activity were assessed in the VTA and NAc following an injection of ruboxistaurin to the NAc 
30 min prior to tissue collection or into the VTA 18 hr prior to tissue collection. A 30 min 
pretreatment of ruboxistaurin in the NAc attenuated AMPH-stimulated locomotor activity, but 
not an 18 hr pretreatment. An 18 hr pretreatment of ruboxistaurin, but not a 30-min pretreatment, 
in the VTA attenuated AMPH-stimulated locomotor activity. PKCβ and pGAP43 levels were 
decreased in the VTA following an 18 hr pretreatment into the VTA. Following a 30 min 
injection into the NAc, pGAP43 was decreased in the NAc but not the VTA. These data suggest 




inhibitors act indirectly in the VTA to decrease behaviors, likely through a downregulation of 
PKCβ. 
Introduction 
Amphetamines (AMPH) are a class of stimulants that are commonly used worldwide. 
AMPHs increase alertness and attention and are often prescribed for attention deficit 
hyperactivity disorder in the form of Adderall, but long-term misuse of AMPH can lead to 
cognitive deficits and psychosis (Heal et al. 2013; Janowsky and Risch 1979). AMPHs’ 
reinforcing effects often lead to their misuse; they are the second most common class of drug 
abused worldwide (UNODC 2018). Furthermore, misuse of prescription stimulants during 
adolescence is correlated with higher rates of drug use in adulthood (McCabe et al. 2017). 
Despite their prevalence, there is currently no good therapeutic option for AMPH-use disorder 
beyond behavioral therapy (UNODC 2016b).  
The reinforcing effects of AMPH are due to the dysregulation of dopamine primarily in 
dopaminergic neurons extending from the ventral tegmental area (VTA) to the nucleus 
accumbens (NAc) (Di Chiara and Imperato 1988). These neurons are part of the mesolimbic or 
“reward” pathway; dopamine release along this pathway regulates locomotor activity, motivation 
and reinforcement (Volkow et al. 2004). Extracellular dopamine levels in the NAc are regulated 
by the dopamine transporter (DAT), which removes dopamine from the synapse to terminate 
dopaminergic signaling in the brain. AMPHs enter neurons through DAT and reverse the 
direction of the transporter, resulting in the release of dopamine into the extracellular space and 
an increase in dopaminergic signaling (Seiden et al. 1993).  
Protein kinase Cβ (PKCβ) is a signaling protein that is important for AMPH’s action. 




release (Giambalvo 1992a; b; Kantor and Gnegy 1998). PKCβ, in particular, is the isoform of 
PKC necessary for AMPH action (Chen et al. 2009; Johnson et al. 2005). Furthermore, 
pharmacological or genetic inhibition of PKC attenuates AMPH-stimulated locomotor activity 
(Carpenter et al. 2017; Chen et al. 2009; Zestos et al. 2016). Our group has also demonstrated 
that PKCβ inhibition decreases responding for AMPH in a self-administration paradigm (Chapter 
2). All together, these studies suggest that PKCβ inhibitors are viable therapeutic options for the 
treatment of AMPH-use disorder.  
One conundrum is that the time course of action for the PKC inhibitors differs depending 
on the route of administration. When tamoxifen, a brain-permeable PKC inhibitor, was 
administered peripherally, a single acute injection was not sufficient to decrease AMPH-
mediated behaviors (Einat et al. 2007; Mikelman et al. 2018). Interestingly, a peripheral injection 
of 6c, a tamoxifen analog, decreased amphetamine-stimulated dopamine release when 
administered simultaneously with AMPH and when administered 18 hr before AMPH, however 
only an injection followed by an extended period of time was sufficient to decrease AMPH self-
administration (Carpenter et al. 2017). Our studies with enzastaurin, a PKCβ-selective inhibitor, 
that both dose and time after treatment were crucial for its ability to reduce the behavioral effects 
of AMPH. A high dose of enzastaurin (1 nmol) was sufficient to decrease AMPH-stimulated 
locomotor activity acutely, but a low dose (10-30 pmol) required 18 hr before effectively 
attenuating locomotor activity. When low doses of a PKC inhibitor (9-30 pmol) were injected 
directly into the NAc, they acutely decreased AMPH-stimulated behaviors (Browman et al. 
1998; Zestos et al. 2016). The discrepancy in action at different time points suggests that PKCβ 




Understanding these mechanisms is a necessary step in moving PKCβ inhibitors forward 
as therapeutic options and graining a greater understanding of regulation of dopaminergic 
activity. Additionally, knowledge behind the action of these drugs may provide useful 
information for the treatment of other psychiatric disorders such as bipolar disorder and post-
traumatic stress disorder (Mochly-Rosen et al. 2012). The goal of this study is to investigate 
whether PKCβ inhibitors decreased AMPH-mediated behaviors through different mechanisms 
depending on the brain region or time course of PKCβ administration.  Phosphorylation-related 
alterations in protein levels and function will be assessed to track the biological function of the 
inhibitors and provide mechanistic information. We found that AMPH-stimulated locomotor 
activity was decreased when ruboxistaurin, a PKCβ-selective inhibitor, was injected acutely in 
the NAc but only after 18 hr when injected into the VTA. Conversely, no change in AMPH-
stimulated locomotor activity was evident 18 hr after injection in the NAc or acutely after 
injection in the VTA. As expected, an acute treatment of ruboxistaurin in the NAc inhibited PKC 
activity. However, there was a decrease in PKC levels in the VTA following the extended time 
period, which mirrored the changes in locomotor behavior. These studies suggest PKCβ 
inhibition directly decreases AMPH-stimulated locomotor activity in the NAc but acts through 
an indirect mechanism (likely the downregulation of PKCβ) in the VTA.  
Methods 
Subjects: Male Sprague-Dawley rats (Harlan Laboratories, Indianapolis, IN) were single-housed 
in a humidity and temperature-controlled environment. All animals were on a 12-hr light/dark 
cycle and all testing was done during the light phase. Food was available to the rats ad libitum. 




and Use Committee and designed within the rules and regulations of the National Research 
Council Guide for the Care and Use of Laboratory Animals. 
Drug Solutions: D-AMPH (National Institute on Drug Abuse, Bethesda, MD) was dissolved in 
saline and administered subcutaneously (s.c.). Carprofen (Zoetis, Parsippany, NJ) was diluted in 
saline and administered s.c. Ketamine (Hospira, Lake Forest, IL) and xylazine (Akorn, Lake 
Forest, IL) were administered intraperitoneally. Ruboxistaurin (National Institute of Health, 
Bethesda, MD) was dissolved in artificial cerebral spinal fluid (Durect, Cupertino, CA) and 
0.005% dimethyl sulfoxide (DMSO) and administered directly into the brain.  
Ruboxistaurin was administered over a programmable pump that administered 0.5 µl at a rate of 
0.25 µl/min bilaterally into the NAc core or the VTA. The rats were awake throughout the course 
of drug administration. Tygon tubing connected an infusion cannula (NAc: 8IC313ISPCXC 28 
GA 6.4 mm with a 2 mm projection, VTA:  C232I/SPC 28 GA 7.5 mm with a 2 mm projection, 
Plastics One, Roanoke, VA) to a single channel plastic swivel (275/22PS, Instech Laboratories, 
Plymouth Meeting, PA) suspended on a counter-balanced arm (PHM-110-SAI, Med Associates, 
Fairfax, VT). A 10 µl Hamilton syringe was attached via Tygon tubing to the other end of the 
plastic swivel. 
Cannula implantation: Rats were implanted with a guide cannula (NAc: C313G-L14/SP 22 GA 
with 6.4 mm projection, VTA: C232G-1.0/SPC 22 GA with 7.5 mm projection, Plastics One) to 
allow for direct injections. The rats received 5 mg/kg carprofen and ketamine/xylazine (90:10 
i.p.). They were placed in a stereotaxic instrument (Kopf Instruments, Tujunga, CA) and 
cannulae were implanted relative to bregma [NAc: AP = +1.4 mm, ML = ±1.5 mm, DV = -5.5 
mm, VTA: AP = -5.7 mm, ML = ±0.5 mm, DV = -6.9 mm (Paxinos and Watson 2005)]. The 




One) and covered with a dust cap (303DC/1, Plastics One). Everything was anchored in place 
with dental cement (OrthoJet-BCA, Lang Dental Manufacturing Co., Wheeling, IL) and two 
steel screws (19010-10, Fine Science Tool, Foster City, CA). Placement was confirmed in 
locomotor activity rats by anesthetizing the rats and infusing Fast Green FCF (Millipore Sigma, 
Darmstadt, Germany) into the cannula. Their brain was collected and frozen in isopentane and 
dry ice. The brains were sliced with a cryostat (Leica CM1850, Buffalo Grove, IL) and mounted 
on slides, then examined for dye distribution.  
 
Figure 4.1 Schematic representing experimental timeline  
(a) Demonstrates the time line for locomotor activity assays. Four groups of rats were tested in 
the locomotor activity assays. The first and second group were administered vehicle or 
ruboxistaurin into the VTA or the NAc 18 hr before AMPH. The third and fourth group received 
vehicle or ruboxistaurin into the VTA or NAc 30 min before AMPH administration. All groups 
were habituated to the locomotor activity cages 1.5 hr before AMPH administration and 
received an injection of saline 30 min before AMPH administration. (b) One group of rats 
received vehicle or ruboxistaurin into the VTA 18 hr before administering AMPH. The second 
group of rats received vehicle or ruboxistaurin in the NAc 30 min before administering AMPH. 





Locomotor activity: Rats were placed in an acrylic cage containing infrared beams (Opto-M3 
Activity Monitor) as described in Chapter 2. Rats were injected with saline (s.c.) and habituated 
to the cage for 60 min. They were then given a second saline injection followed 30 min later by 1 
mg/kg AMPH (s.c.). Activity for the rats was recorded for 2.5 hr following the AMPH injection. 
Two groups of rats were injected with vehicle or 10 pmol ruboxistaurin directly into the NAc or 
the VTA (10 pmol / 2 min)18 hr prior to AMPH administration. Two more groups were injected 
with vehicle or ruboxistaurin directly into the NAc or VTA (10 pmol / 2 min) directly before the 
second saline injection, 10 min prior to AMPH administration (Figure 4.1).  
Immunoblotting: Rats were administered vehicle or 10 pmol ruboxistaurin directly into the NAc 
or VTA 30 min or 18 hr prior to an injection of 1 mg/kg AMPH (s.c.). VTA and striatal tissue 
were collected 10 min following the AMPH or saline injection and the samples were 
immediately frozen in isopentane. Boiling 1% SDS was added to each sample and the samples 
were sonicated at a frequency of 20 kHz (sonic dismembrator, Fisher Scientific, Pittsburgh, PA), 
then centrifuged at 14,000 rpm, 4°C. The samples were separated by gel electrophoresis on a 
12% SDS-PAGE gel. The proteins were transferred to a nitrocellulose membrane at 1 A for 1 hr. 
The membranes were blocked in a buffer (5% w/v milk, 150 mM NaCl, 10 mM Tris, 0.05% 
Tween20) before probing for anti-growth associated protein 43 (GAP43) and anti-phosphoser41-
GAP43 (pGAP43) (both anti-goat, Santa Cruz Biotechnology, Santa Cruz, CA), PKCβII (anti-
rabbit, Santa Cruz Biotechnology) and GAPDH (anti-rabbit, Cell Signaling Technology, 
Danvers, MA) overnight at 4°C. The membranes were washed with a wash buffer (150 mM 
NaCl, 10 mM Tris, 0.05% Tween20) three times before being incubated with secondary 
antibodies for 1 hr at room temperature: horseradish peroxidase (HRP)-tagged goat anti-rabbit 




GAP43 and pGAP43 (Santa Cruz Biotechnology). The antibodies were imaged with 
Chemiluminescent Western Substrate (EMD Millipore, Darmstadt, Germany) and band densities 
were quantified using ImageJ software (Schneider et al. 2012).  
Statistical Analysis: Statistical analyses were performed using GraphPad Prism 8.0 (GraphPad 
Software Inc, San Diego, CA). Two-way ANOVAs were used to compare locomotor data with 
Dunnett’s multiple comparisons post hoc tests. Immunoblotting data were analyzed by a 
parametric t-test. Alpha level was set at 0.05.  
Results 
 
Figure 4.2 Verification of cannula placement into the NAc and VTA. 
 Panels display coronal sections (adapted from The rat brain in stereotaxic coordinates, 5th 
edition) from the NAc (1a) and the VTA with black circles indicating cannula placement in rats 





Figure 4.3 Ruboxistaurin attenuated AMPH-stimulated locomotor activity when 
administered into the NAc after 30 min and into the VTA after 18 hr.  
The effects of ruboxistaurin on locomotor activity was assessed in rats 30 min or 18 hr after 
injections into different brain regions. Their baseline (BL) is calculated as the average number of 
beam breaks over 30 min following a saline injection (s.c.). At the end of the 30 min of saline, 
rats were injected with 1 mg/kg AMPH (s.c.). The number of beam breaks are summed into 10 
min bins. Rats were pretreated with vehicle (open squares) or 10 pmol ruboxistaurin (closed 
squares).  Ruboxistaurin was administered directly into the NAc 30 min (a) or 18 hr (b) before 
administration of AMPH or into the VTA 30 min (c) or 18 hr (d) before administration of 
AMPH. * p < 0.05, ** p < 0.01, **** p < 0.0001 ruboxistaurin vs. vehicle pretreatment. n=6 
 
The effect of ruboxistaurin on AMPH-stimulated locomotor activity is time and location 
dependent.  
In order to determine the role that time course and brain region played in the behavioral effects 
of ruboxistaurin, we administered 10 pmol ruboxistaurin directly into the NAc (Figure 4.3 a, b) 




30-min pretreatment of ruboxistaurin into the NAc (Figure 4.3 a), but not an 18-hr pretreatment 
(Figure 4.3 b) significantly decreased AMPH-stimulated locomotor activity, without altering 
locomotor activity [two-way ANOVA: significant interaction between time and 
vehicle/ruboxistaurin pretreatment F(15, 120) = 2.802, p = 0.0009 and a significant main effect 
of time F(15, 120) = 31.47, p < 0.0001]. Conversely, an 18-hr pretreatment of ruboxistaurin into 
the VTA (Figure 4.3 d), but not a 30-min pretreatment (Figure 4.3 c), significantly decreased 
AMPH-stimulated locomotor activity [two-way ANOVA: significant interaction between time 
and vehicle/ruboxistaurin pretreatment F(15, 120) = 2.08, p = 0.0152 and significant main effects 
of time F(15,120) = 48.95, p < 0.0001, and vehicle/ruboxistaurin pretreatment F(1, 8) = 7.169, p 
= 0.0280]. There was no significant change in locomotor activity before AMPH administration. 
 
Figure 4.4 Decreased PKC activation in the NAc following a 30 min pretreatment of 




NAc (a, b) and VTA (c, d) tissue from rats treated with vehicle or 10 pmol ruboxistaurin into the 
NAc 30 min before AMPH were collected and probed for phosphoser41-GAP43 (pGAP43) and 
total PKCβII (tPKC). The data are presented as the ratio of the optical density of 




 Figure 4.5 Decreased PKC levels and activation in the VTA following an 18 hr 
pretreatment of ruboxistaurin into the VTA. 
 NAc (a, b) and VTA (c, d) tissue from rats treated with vehicle or 10 pmol ruboxistaurin into 
the VTA 18 hours before AMPH were collected and probed for phosphoser41-GAP43 (pGAP43) 
and total PKCβII (tPKC). The data are presented as the ratio of the optical density of 
pGAP43/GAPDH (a, c) and tPKC/GAPDH (b, d) ± SEM (n=6). * p < 0.05 vs. vehicle 
pretreatment. n=6 
 
Ruboxistaurin administered into the VTA 18 hr before AMPH administration decreased 




We sought to identify changes in the brain that corresponded with a decrease in locomotor 
activity. Rats were administered vehicle or ruboxistaurin (10 pmol) into the NAc 30 min before 1 
mg/kg AMPH s.c. A second group of rats were administered VTA vehicle or ruboxistaurin 18 hr 
before 1 mg/kg AMPH s.c.  NAc and VTA tissue were collected from both groups 10 min after 
AMPH administration and blotted for PKCβII and pGAP43 and tGAP43 (data not shown). As 
might be expected, a 30 min treatment with the PKC inhibitor ruboxistaurin into the NAc 
significantly decreased pGAP43 levels in the NAc (t-test p = 0.04) as compared to vehicle 
(Figure 4.4a).  There were no changes in pGAP43 in the VTA, nor in total PKCβII content in 
either the NAc or VTA following the 30 min injection into the NAc (Figure 4.4 b, c, d).  In the 
second group of rats, a t-test determined that ruboxistaurin treatment given 18 hours prior to 
AMPH significantly decreased pGAP43 (p = 0.02) in the VTA as compared to vehicle (Figure 
4.5 c, d) but there was also a significant decrease in total PKCβII (p = 0.04). There were no 
significant changes in pGAP43 or PKCβII in the NAc when ruboxistaurin was injected into the 
VTA (Figure 4.5 a, b). There were no changes in total GAP43 in any group (data not shown).  
Discussion 
In this study, we demonstrate for the first time that ruboxistaurin inhibits AMPH-
mediated behavior through both direct and indirect mechanisms depending on the brain region. 
Previous studies have shown that ruboxistaurin and other PKC inhibitors injected directly in the 
NAc 15-30 min before AMPH administration decrease AMPH-stimulated locomotor activity 
(Browman et al. 1998; Loweth et al. 2009; Zestos et al. 2016). On the contrary, PKC inhibitors 
decrease AMPH-mediated behaviors following extended pretreatment times when administered 
i.c.v. or s.c., indicating that PKC inhibition may elicit a secondary mechanism that can alter 




compare the actions of ruboxistaurin in two brain regions of the mesolimbic dopamine pathway, 
the NAc and VTA. Ruboxistaurin decreased AMPH-stimulated locomotor activity when 
administered into the NAc 30 min or into the VTA 18 hr before AMPH, while the converse, 18 
hr in the NAc or 30 min in the VTA before AMPH was ineffectual. Biochemical analysis of 
these different brain regions demonstrated the expected decrease in local PKC activity following 
a short (30 min) pretreatment into the NAc.  Notably, however, following a long pretreatment in 
the VTA, we found a decrease in both pGAP43 and total PKCβII levels rather than merely an 
inhibition of PKC activity. These findings indicate that ruboxistaurin acts directly in the NAc to 
decrease PKC activity and locomotor activity but acts indirectly in the VTA to reduce locomotor 
activity and PKC activity by decreasing PKCβII levels.  
The effect of ruboxistaurin on AMPH-stimulated locomotor activity differed depending 
on the brain region and pretreatment time. The finding that a short pretreatment time (30 min) 
was effective in the NAc but a long pretreatment time (18 hr) was only effective in the VTA 
indicates that the mechanisms of ruboxistaurin action are different in the NAc compared to the 
VTA. Most likely, acute ruboxistaurin in the NAc is inhibiting AMPH-stimulated locomotor 
activity by decreasing AMPH-stimulated dopamine efflux through DAT, following the known 
mechanism of PKC inhibition of AMPH action (Chen et al. 2009; Giambalvo 1988; Johnson et 
al. 2005; Kantor and Gnegy 1998).  
A longer pretreatment time of PKC inhibitor is likely acting through a secondary 
mechanism downstream of PKC. To further probe the action of ruboxistaurin in the VTA, we 
examined how PKCβII levels and activity were affected 18 hr following ruboxistaurin 
administration into the VTA. We looked at PKCβII in particular because PKCβII has been 




PKC (Johnson et al. 2005), and this isoform is known to be expressed around the NAc and the 
VTA (O'Malley et al. 2010; Saito et al. 1989). A long pretreatment saw a decrease in PKC 
activity and PKCβII levels in the VTA raising the possibility that a decrease in PKC levels may 
account for the behavior.  
 Interestingly, the administration of a PKC inhibitor into the VTA did not alter PKC 
activity in the NAc despite the extended pretreatment. This was unexpected as acute effects of 
AMPH on locomotor activity occur when AMPH is injected into the NAc but not the VTA 
(Perugini and Vezina 1994; Vezina and Stewart 1990). Furthermore, we previously demonstrated 
that PKCβ inhibitors administered i.c.v. 18 hr before tissue collection decrease PKC activity in 
the NAc (Chapter 2). It is possible that there was a decrease in PKC activity in dopaminergic 
neurons in the NAc, but since the NAc contains a heterogenous mix of cells, any decrease in 
PKC activity may be obfuscated by the other cells within the samples. This was likely not an 
issue following i.c.v. administration of a PKC inhibitor, as we were not targeting specific brain 
regions. Additional studies examining changes specifically in presynaptic dopamine neurons in 
the NAc would be able to verify a decrease in PKC activity.  
 Multiple mechanisms can lead to a decrease in PKC levels. One possibility is that 
PKCβII is downregulated. The VTA contains the cell bodies of the dopaminergic neurons in the 
mesolimbic pathway, therefore changes in protein transcription occurs in the VTA. PKCs 
interact with many different transcription factors to regulate gene expression (Ventura and 
Maioli 2001). It is well known that activators of PKC increase degradation of PKC and 
downregulate the enzyme (Ballester and Rosen 1985; Lum et al. 2013), but downregulation of 
PKC following administration of an inhibitor is not entirely unprecedented. One group 




2004) and another group has shown that increased PKCβII increases promotor activity and 
mRNA levels (Cejas et al. 2005). Together, these studies indicate that PKCβII acts in positive 
and negative directions to affect its own synthesis.  Additional studies have also shown that 
tamoxifen or enzastaurin downregulated different isoforms of PKC in cell-based assays 
(Gundimeda et al. 1996; Jane and Pollack 2008). An additional mechanism that may regulate 
PKC levels in the VTA is through increased degradation of PKC. Previous studies have 
demonstrated that an acute pretreatment with an active site inhibitor structurally similar to 
ruboxistaurin, bisindoylmaleimide I, protects PKC from degradation (Gould et al. 2011), 
however the stability of PKC following metabolism or elimination of the inhibitor is not 
understood.  
 Outside of changes in PKC levels, PKC inhibitors may alter AMPH-mediated behaviors 
through other means. PKC is important for the trafficking and regulation of many proteins that 
may play a role in AMPH’s action. The trafficking of D2 and D3 autoreceptors in particular are 
regulated by PKCβ (Cho et al. 2007; Luderman et al. 2015; Namkung and Sibley 2004). PKC is 
also known to affect DAT internalization (Sorkina et al. 2005) so PKCβ inhibition may be 
changing surface levels of DAT. It is also possible that PKC may regulate gene expression of 
proteins that interact with dopamine receptors or DAT or their downstream effectors.   
Additional effects of ruboxistaurin may underlie its actions on AMPH-mediated 
behaviors following a long pretreatment. One potential mechanism is that an active metabolite of 
ruboxistaurin could decrease AMPH-mediated actions in the brain. A study looking at [14C]-
ruboxistaurin in a rat following oral administration determined the half-life for ruboxistaurin and 
its active metabolite to be 2.5 and 4.3 hr, respectively; remaining levels of 14C could indicate 




metabolism as a factor on AMPH-stimulated behaviors, the fact that the prolonged time course is 
seen across a variety of structurally unrelated PKC inhibitors (bisindoylmaleimides such as 
enzastaurin and ruboxistaurin and tamoxifen analogs) indicate that the time course may be due to 
the mechanism of the drugs rather than their pharmacokinetics.  
 In conclusion, we have demonstrated that ruboxistaurin, a PKCβ selective inhibitor, may 
be altering AMPH-stimulated behaviors through a direct mechanism and an indirect mechanism. 
A potential explanation behind the indirect mechanism may be by decreasing PKCβII levels in 
the mesolimbic pathway. This does not mean that a decrease in PKC levels is the only effect of a 
long pretreatment with PKC inhibitors; additional proteins that may be affected and can play a 
role in AMPH-mediated behaviors include dopamine receptors and their downstream effectors. 
Future studies should identify additional mechanisms and explore the specific proteins 
downstream of PKC that may play a role in this effect. These studies provide the first step in 
understanding an additional mechanism important for the action of PKC inhibitors and add to our 
understanding of the therapeutic potential of such inhibitors for the treatment of substance-use 
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Chapter 5 Discussion 
Amphetamine abuse is prevalent throughout the United States and the world and presents 
a serious public health concern (Miech et al. 2018; UNODC 2016a; 2018). Despite the wide-
spread use of amphetamine, the only treatments for amphetamine-use disorder are cognitive or 
behavioral therapies (UNODC 2016b), and a large percentage of patients treated for misuse of 
amphetamine-type stimulants relapse within a year (Brecht and Herbeck 2014). This highlights 
the unmet need for a pharmacological intervention to supplement treatment for amphetamine-use 
disorders. Protein kinase Cβ (PKCβ) is a potential target for a novel therapeutic. Years of 
research have demonstrated that PKC, in particular PKCβ, inhibitors block the actions of 
amphetamine ex vivo and in vivo (Browman et al. 1998; Chen et al. 2009; Johnson et al. 2005; 
Kantor and Gnegy 1998). 
In this thesis, I demonstrate that PKCβ inhibitors decrease amphetamine-mediated 
behaviors, particularly locomotor activity and reinforcing effects. Furthermore, the experiments 
presented here suggest that PKCβ inhibitors decrease amphetamine-stimulated behaviors through 
more than one mechanism. These studies expand our understanding of PKCβ actions in the brain 
and support the development of PKCβ inhibitors as therapeutics for amphetamine use-disorder.  
PKCβ inhibition and locomotor activity 
 Locomotor activity is a simple, rapid way to investigate amphetamine-induced behavior, 
making it a good first step in characterizing the actions PKCβ inhibitors. Locomotion is an 




conditions (Nader 2016). Stimulants such as amphetamine increase locomotor activity in rats by 
increasing extracellular dopamine levels and dopaminergic signaling in the nucleus accumbens. 
Locomotor activity has long been tied to dopamine transmission in the brain (Beninger 1983; 
Kelly and Iversen 1976; Schindler and Carmona 2002). This led to the hypothesis that PKC 
inhibitors, which attenuate amphetamine-stimulated dopamine efflux, will decrease 
amphetamine-stimulated locomotor activity. In fact, multiple studies have demonstrated that 
administration of a PKC inhibitor directly into the nucleus accumbens blocks amphetamine-
stimulated locomotor activity (Browman et al. 1998; Loweth et al. 2009; Zestos et al. 2016). In 
this thesis, I used locomotor activity to further characterize the effectiveness of PKCβ-selective 
inhibitors. 
 In Chapter 2, I showed that enzastaurin, a PKCβ-selective inhibitor, decreased 
amphetamine-stimulated locomotor activity. Enzastaurin has a poor bioavailability but good 
safety profile, thus it serves as a proof-of-concept to demonstrate the actions of PKCβ inhibition 
on amphetamine-stimulated locomotor activity. I found that small doses of enzastaurin (10-30 
pmol) effectively attenuated amphetamine-stimulated locomotor activity. These doses of 
enzastaurin did not depress locomotor activity on its own, suggesting that the enzastaurin only 
acts when locomotor activity is enhanced. I also demonstrated that enzastaurin shifted the dose-
effect curve for amphetamine-stimulated locomotor activity to the right. At the largest dose 
tested (3.2 mg/kg amphetamine), locomotor activity for rats pretreated with enzastaurin was 
significantly higher than for the vehicle pretreated rats. This is likely due to the onset of 
stereotypy; short, repetitive movements that interfere with ambulatory locomotor activity, often 




quantified in these experiments, but the enzastaurin-pretreated rats appeared to display less 
stereotyped behaviors and more ambulatory activity than the vehicle-pretreated rats.  
 The most unexpected finding in these studies was the time course of enzastaurin. 
Previous studies looking at PKC inhibitors, including enzastaurin, that were delivered directly to 
the NAc saw a decrease in amphetamine-stimulated activity within 30 min of PKC inhibitor 
administration (Browman et al. 1998; Loweth et al. 2009; Zestos et al. 2016). Our studies found 
that a large dose of enzastaurin given i.c.v. has an acute effect on amphetamine-stimulated 
locomotor activity; however small doses of enzastaurin given i.c.v. needed to be administered 18 
hr before amphetamine to decrease amphetamine-stimulated locomotor activity. These findings 
were not exclusive to enzastaurin; an 18-hr pretreatment was necessary for i.c.v. ruboxistaurin to 
be effective at decreasing locomotor activity (Figure 5.1). The long pretreatment time was 
unexpected, given that i.c.v. administration should bypass pharmacokinetic parameters such as 
absorption and distribution. Furthermore, given the known pharmacokinetics of these drugs, the 
likelihood that enzastaurin or ruboxistaurin or their active metabolites are present at 18 hr is 
minimal. However, a prolonged time course for a PKC inhibitor is not unprecedented. 
Tamoxifen, a brain permeable PKC inhibitor, did not decrease amphetamine-mediated locomotor 
activity acutely and required repeated dosing (Einat et al. 2007; Mikelman et al. 2018). One 
explanation for this effect is that tamoxifen required repeated dosing to accumulate in the brain. 
However, it is not known if a single injection of tamoxifen would attenuate amphetamine-
stimulated locomotor activity following a long pretreatment. As multiple PKC inhibitors have 
been shown to reduce amphetamine action at later time points, it is possible that the prolonged 




PKC inhibition. The time course of PKC inhibitors will be addressed further in a later section of 
this chapter.  
 
 
Figure 5.1 Ruboxistaurin decreased amphetamine-stimulated locomotor activity.  
Rats were administered vehicle or 10 pmol ruboxistaurin i.c.v. 18 hr before receiving 1 mg/kg 
AMPH s.c. Locomotor activity is presented as the number of beam breaks over 10 min bins. 
Baseline activity (BL) was calculated from the average number of beam breaks/10 min bin 30 
min prior to amphetamine administration. A two-way ANOVA showed a significant interaction 
between vehicle/ruboxistaurin and time [F (15, 150) = 1.9, p = 0.03] as well as a significant main 
effect of time [F (15, 150) = 45.43, p < 0.0001] and vehicle/ruboxistaurin [F (1, 10) = 6.03, p = 
0.03]. * p < 0.05. n = 5-7. 
 
 While PKCβ inhibitors successfully decrease amphetamine-stimulated locomotor 
activity, it is not known if these effects are selective for amphetamine or affect the activity of 
other drugs of abuse. One drug of abuse that may be affected by PKC inhibition is cocaine. 
Zestos et al. found that ruboxistaurin injected directly into the NAc reduced cocaine-stimulated 
(15 mg/kg i.p.) dopamine overflow and locomotor activity (Zestos et al. 2018). Despite these 




stimulated locomotor activity (15 mg/kg i.p.) (Figure 5.2a). There appears to be a trend towards 
i.c.v. enzastaurin increasing cocaine-stimulated locomotor activity, thus a full dose effect curve 
needs to be evaluated for cocaine-stimulated locomotor activity to determine if enzastaurin has 
any effect. Additionally, the time course of enzastaurin action on cocaine should be considered. I 
also examined whether i.c.v. enzastaurin would alter SKF-81297 (D1-selective agonist) 
locomotor activity (Figure 5.2b). Again, a full dose-response curve should be evaluated with 
SKF-81297 at different time points. More studies evaluating dose-effects curves with different 
direct and indirect dopamine agonists are necessary to determine if PKCβ selectively attenuates 




Figure 5.2 Enzastaurin did not significantly attenuate cocaine- or SKF-81297-mediated 
locomotor activity.  
Rats were pretreated with vehicle or 10 pmol enzastaurin 18 hr prior to receiving (a) 15 mg/kg 
cocaine i.p. (n = 5-6) or (b) 3.2 mg/kg SKF-81297 s.c. (n = 3). Data are presented as the number 
of beam break over time in 10 min bins. Baseline (BL) is calculated from the average number of 
beam breaks/10 min 30 min before cocaine or SKF-81297 administration. A two-way ANOVA 
did not reveal a significant interaction between time and pretreatment (vehicle vs enzastaurin) or 




PKCβ inhibition and self-administration 
 Locomotor activity assays are perfect for the initial studies characterizing new 
therapeutics, but these assays have many limitations. The biggest limitation to locomotor activity 
as a model for studying drugs of abuse is that it does not model behaviors associated with 
substance-use disorder and is not a measure of drug reinforcement. Drug self-administration 
assays are the most common model to assess drug reinforcement as they directly model drug-
taking and drug-seeking behaviors. These models have been used to accurately predict drug self-
administration in humans (Griffiths et al. 1979) and have predictive validity in assessing new 
medications for certain substance-use disorders (Egli et al. 2016). Predictive validity has yet to 
be shown for amphetamine-use disorders due to a dearth of clinically-approved therapeutics 
(Egli et al. 2016). In order to evaluate a pharmacological intervention/treatment for 
amphetamine-use disorder, the effect of PKCβ inhibitors on the reinforcing effects of 
amphetamine must be evaluated. Through self-administration models, I have determined that 
PKCβ inhibitors decrease the reinforcing properties of amphetamine in rats.  
 In Chapter 2, I demonstrated that 10 pmol enzastaurin (the most effective dose in 
locomotor activity assays) i.c.v.  attenuates responding for amphetamine (0.032 mg/kg/inf) under 
a fixed-ratio (FR) 5 schedule of reinforcement. This dose of enzastaurin was only effective when 
administered 18 hr prior to the self-administration session. A 3 hr pretreatment had no effect on 
responding for amphetamine, and preliminary data suggest that a 1 hr pretreatment also has no 
effect (data not shown). As the dose-effect curve for amphetamine self-administration is an 
inverted U-shaped curve, it is important to evaluate whether enzastaurin attenuates responding 
for multiple doses of amphetamine (Mello and Negus 1996). An ideal therapeutic for substance-




A rightward shift in the dose-effect curve could be interpreted as decreased sensitivity to the self-
administered drug but leads to concerns about increased drug intake at higher doses (Piazza et al. 
2000). When I tested the full dose-effect curve for amphetamine self-administration, I found 10 
pmol enzastaurin shifted the ascending limb of the dose-effect curve without changing the 
descending limb. This shift in the dose-effect curve is not a typical downward or rightward shift, 
suggesting decreased drug-intake at lower doses of amphetamine without a corresponding 
increase in drug-intake at higher doses. An explanation for the direction of this shift may be due 
to experimental design. The dose-effect curve for amphetamine was assessed within a single 
session so it is possible that enzastaurin was surmounted by high doses of amphetamine in the 
later components of the session.  
 One concern about using a PKCβ inhibitor as a therapeutic is that the inhibitor would 
decease all operant responding due to adverse effects, so sucrose self-administration was used as 
a control. Enzastaurin did not alter responding for sucrose under an FR5 schedule of 
reinforcement. These studies demonstrate that enzastaurin does not suppress all behaviors and 
functions necessary for operant responding. While these findings may also indicate a selectivity 
for amphetamine over non-drug reinforcers, a concentration-effect curve with sucrose would 
need to be evaluated in order to fully assess enzastaurin selectivity.  
 The studies in Chapter 2 demonstrated that a PKCβ inhibitor affects drug-taking 
behaviors. To further corroborate my findings that PKCβ inhibitors decrease the reinforcing 
properties of amphetamine, I used the progressive-ratio (PR) schedule of reinforcement (Arnold 
and Roberts 1997). In Chapter 3, I demonstrated a decrease in the reinforcing strength of 
amphetamine following a pretreatment with a PKCβ inhibitor. It has also been suggested that a 




craving amphetamine (Markou et al. 1993). Furthermore, as with the previous sucrose studies, 
the PKCβ inhibitor did not affect responding for sucrose under a PR schedule, suggesting that 
PKCβ inhibition does not affect the rewarding strength of a non-drug reinforcer.  
 These proof-of-concept studies with enzastaurin and ruboxistaurin overall demonstrate 
that PKCβ is a reasonable target to attenuate amphetamine-stimulated behaviors, including 
amphetamine-taking behavior. These compounds cannot be repurposed or developed for the 
treatment of amphetamine use disorder because these compounds do not cross the blood brain 
barrier following peripheral administration. Since there are few to no studies published on brain-
permeable PKC inhibitors (Mochly-Rosen et al. 2012), efforts were made to use the tamoxifen 
scaffold to develop a blood-permeable PKC inhibitor without the anti-estrogenic properties of 
tamoxifen (Carpenter et al. 2016). The lead compound from these studies, 6c, successfully 
attenuates amphetamine-stimulated dopamine release in vivo following peripheral 
administration. More importantly, it decreases amphetamine self-administration under an FR 
schedule (Carpenter et al. 2017) and a PR schedule (Chapter 3), without affecting responding for 
sucrose. 6c needs to be examined with a full amphetamine dose-effect curve, but these initial 
findings are a promising start in identifying new compounds. Interestingly, 6c also displayed the 
same delayed activity as the structurally unrelated compounds enzastaurin and ruboxistaurin and 
required long pretreatments to have any effect in the self-administration models. These findings 
are consistent with my hypothesis that the extended time necessary for action may be more 
related to the pharmacodynamic actions of PKC inhibitors as opposed to pharmacokinetic 
measures.  




 A common theme throughout these studies is that PKCβ inhibitors require long 
pretreatments before effectively decreasing amphetamine-mediated behaviors. This has raised 
two main, albeit related, questions: 
(1) Why do PKCβ inhibitors given i.c.v. not act acutely? 
(2) Why do PKCβ inhibitors require long pretreatment times? 
Other studies have already demonstrated that PKCβ inhibitors act acutely (Loweth et al. 
2009; Zestos et al. 2016), however a common feature among these studies is that the drugs were 
administered directly into the NAc. In trying to reconcile these findings, what stands out most is 
the differences between routes of administration. A direct drug injection into the NAc will 
concentrate the drug within the NAc whereas an i.c.v. injection would distribute a drug 
throughout the brain (Luger et al. 2005), resulting in less drug accumulation in the NAc. 
Therefore, I hypothesized that giving a larger amount of PKCβ inhibitor i.c.v. should decrease 
amphetamine-stimulated activity. Consistent with this prediction, I found that a large dose (1 
nmol enzastaurin i.c.v.) could decrease amphetamine-stimulated locomotor activity following a 
30 min pretreatment (Chapter 2). I also demonstrated that 10 pmol ruboxistaurin directly into the 
NAc decreased amphetamine-stimulated locomotor activity following a 30 min pretreatment 
(Chapter 4). These findings support the hypothesis that drug concentration in the NAc is 
important for the behavioral effects of these inhibitors although future studies quantifying drug 
concentration in these brain regions are necessary.  
 To further probe the mechanism involved in the effects observed following the long 
pretreatment time, I compared drug action in the NAc to a different region in the mesolimbic 
pathway, the ventral tegmental area (VTA). Direct injections of a PKCβ inhibitor into the NAc 




NAc were ineffective at modulating locomotor activity. PKCβ inhibition had the opposite effects 
in the VTA; long pretreatments, but not acute pretreatments, of ruboxistaurin attenuated 
amphetamine-stimulated locomotor activity. These findings have two main implications: (1) the 
brain region is an important determinant of PKCβ inhibitor action and (2) a long pretreatment 
with PKCβ inhibitors may decrease amphetamine action through a different mechanism as 
compared to an acute pretreatment.   
 There are many potential explanations behind the effectiveness of a long pretreatment. 
Drug metabolism is one such explanation, however the pharmacokinetic studies for the half-lives 
of enzastaurin (personal communications with Eli Lilly and Denovo Biopharma) and 
ruboxistaurin (Campanale et al. 2002) do not support an 18 hr time course. One caveat is that the 
pharmacokinetic studies were performed following oral administration of the drugs, not i.c.v. 
Further complicating this explanation, the effectiveness of a long pretreatment time was also 
established with the 6c and it is unlikely that the structurally unrelated compound has a similar 
pharmacokinetic profile to enzastaurin and ruboxistaurin.  
Another explanation for the prolonged time course is that changes in protein expression 
due to PKC inhibition are responsible for the decrease in amphetamine-mediated behaviors. PKC 
activity is an important factor in many signaling pathways and can control expression of different 
genes and proteins (Ventura and Maioli 2001). Furthermore, the cell bodies of the neurons in the 
mesolimbic pathway are in the VTA, highlighting the importance of drug activity in that brain 
region. To support this explanation, I found that PKCβII levels and activity in the VTA were 
decreased following the 18 hr pretreatment with a PKCβ inhibitor. This was initially a surprising 
find given that multiple studies have demonstrated that activation of PKC downregulates the 




autoregulates activity of the PKCβ promotor (Cejas et al. 2005; Liu et al. 2004). For instance, 
Liu et al. found inhibition of PKCβ with enzastaurin decreased expression of PKCβII mRNA in 
cell cultures (Liu et al. 2004). Taken together, these findings suggest that acute inhibition of 
PKCβ in the NAc decreases amphetamine-mediated behaviors but over time the inhibition of 
PKCβ in the VTA results in the downregulation of PKCβII which contributes to the decrease in 
amphetamine-mediated behaviors 18 hr later.  
Additional targets of PKC inhibitors  
A downregulation of PKCβ is one likely explanation for the prolonged time course of 
PKC inhibitors, but other targets must also be taken into consideration. Due to the ubiquitous 
nature of PKC, it is likely that inhibition will have effects on expression, activity, and trafficking 
of other proteins, including some that are important for amphetamine action. One clear target to 
investigate is the dopamine receptor. The studies with the dopamine D1 receptor agonist SKF-
81297 (Figure 5.2) were not conclusive in determining if there is any change in D1 receptor 
function. Another group found that PKC inhibitors had no effect on D1-agonist-induced 
reinstatement of cocaine seeking (Ortinski et al. 2015), suggesting that PKC inhibition may not 
have much of an effect on D1 receptor activity. Multiple groups have shown that PKC regulates 
trafficking and function of D2-like receptors (Luderman et al. 2015; Namkung and Sibley 2004). 
Zestos et al. found that acute enzastaurin decreased cocaine-stimulated locomotor activity 
through the activation of  D2 autoreceptors (Zestos et al. 2018). While an 18 hr pretreatment of 
i.c.v. 10 pmol enzastaurin had no significant effect on cocaine-stimulated locomotor activity 
(Figure 5.2), evaluating a full dose-effect curve for cocaine may reveal a decrease in locomotor 





Figure 5.3 Ruboxistaurin shifted the yawning dose-effect curve for quinpirole to the right. 
 Rats were pretreated with vehicle (open circles), 10 pmol (grey squares), or 30 pmol (closed 
triangles) ruboxistaurin i.c.v. 18 hr before receiving cumulative doses (0.0032-0.32 mg/kg) of 
quinpirole (s.c.) every 30 min. The number of yawns over a 10 min period were recorded 20 min 
after each injection. A two-way ANOVA demonstrated a significant interaction between dose of 
quinpirole and pretreatment. *** p < 0.001, **** p < 0.0001 vehicle vs 10 pmol ruboxistaurin, 
&&&& p < 0.0001 10 pmol vs 30 pmol ruboxistaurin, $$$$ p < 0.0001 vehicle vs 30 pmol 
ruboxistaurin. n=6. 
 
To assess whether D2-like receptor activity was changed with a long pretreatment time 
with a PKCβ inhibitor, I turned to yawning as a readout of D2 and D3 receptor activity. Low 
doses of quinpirole, a D2/D3 agonist, induce yawning in rodents and high doses decrease 
yawning. Collins et al. (2007) further examined the specific contributions of D2 and D3 receptor 
activation to the induction of yawning and found that D3 receptor activation induces yawning and 
controls the ascending limb of yawning dose-effect curve while D2 activation inhibits yawning 
inducing the descending limb. I pretreated rats with 10 or 30 pmol ruboxistaurin i.c.v. 18 hr 
before administering cumulative doses of quinpirole (Figure 5.3). I found an 18 hr pretreatment 




decrease in potency at the D3 receptor. A decrease in D3-receptor activity could modulate 
amphetamine-mediated behaviors as D3 receptor antagonists have been shown to decrease self-
administration (Higley et al. 2011). A 10 pmol dose of ruboxistaurin appears to shift the 
descending limb to the right, indicating a decrease in potency at the D2 receptor. The higher dose 
of ruboxistaurin, however, does not shows a downward shift, perhaps due to less induction of 
yawning by D3 receptors. Further studies with quinpirole-induced hypothermia, a state controlled 
entirely through D2-receptor activation, would further enhance our understanding of whether 
PKCβ inhibition over time affects D2 receptors. Additional studies could also examine dopamine 
receptor activation, dopamine receptor trafficking, or downstream effectors of dopamine receptor 
signaling to determine how PKCβ inhibition decreases D2-like receptor activity.  
Conclusions 
  PKCβ inhibition is a promising target as a therapeutic for amphetamine-use disorders. I 
have demonstrated that PKCβ inhibitors decrease amphetamine-stimulated behaviors. More 
importantly, PKCβ inhibitors decrease the reinforcing properties of amphetamine in rodents, a 
necessary outcome in the development of therapeutics for substance-use disorders. Finally, I 
showed that PKCβ inhibitors decrease locomotor activity acutely, but then induce a secondary 
effect that decrease amphetamine-mediated behaviors 18 hr after administration. These actions 
likely occur through separate mechanisms. These findings are the first steps or proof of concept 
studies necessary for the development of PKCβ inhibitors for amphetamine use disorder. Further 
studies should examine the effects of repeated dosing over time as well as whether PKCβ 
inhibitors will decrease reinstatement for amphetamine in a relapse model. Finally, further 
characterization of the proteins downstream of PKC signaling will provide important information 




further investigation and development of PKCβ inhibitors as a therapeutic for amphetamine-use 
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